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ABSTRACT 
 
Cooperativity can be used to manipulate binding affinities of DNA biosensors – 
improving specificity without sacrificing sensitivity; examples include tentacle probes 
(TPs) and cooperative primers (CPs). This thesis body of work: (1) used TPs to develop a 
rapid, low-cost diagnostic for detecting the point mutation leading to Navajo 
Neurohepatopathy (NNH) and (2) used CPs to amplify a symmetric bowtie-barcoded 
origami with captured t-cell receptor (TCR) α and β mRNA of a single cell.  
NNH (affecting 1-in-1600 Navajo babies) is a fatal genetic disorder often caused 
by 149G>A mutation and is characterized by brain damage and liver disease/failure. 
Phoenix Children’s Hospital currently uses gene sequencing to identify the 149G>A 
mutation. While this process is conclusive, there are limitations, as it requires both time 
(3-4 weeks) and money (>$700). Ultimately, these factors create barriers that can directly 
impact a patient’s quality of life. Assessment of the developed TP diagnostic, using 
genomic DNA derived from FFPE patient liver samples, suggests nearly 100% specificity 
and sensitivity while reducing cost to ~$250 (including cost of labor) and providing a 
diagnosis within 48 hours.  
TCR specificity is dependent on V(D)J recombination as well as pairing of the αβ 
chains. Drs. Schoettle and Blattman have developed a solution in which a bowtie-
barcoded origami strand nanostructure is transfected into individual cells of a 
heterogeneous cell population to capture and protect αβ mRNA. When PCR of the 
origami template is performed with Vα, X, Vβ, and Y primers, the α and β gene segments 
cannot be tied back to a barcode – and paired. Assessment of the developed CPs for PCR 
  
ii 
suggests correct individual amplification using (1) Va + Xcp and (2) Vβ + Ycp primers, 
whereas combination of all the primers (Va, Xcp, Vb, and Ycp) suggests hybridization of 
the Vα + Xcp and Vβ + Ycp products due to the origami target symmetry. 
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CHAPTER 1  
INTRODUCTION 
Cooperativity 
Cooperativity is where the binding of one ligand to a receptor changes the binding 
of the second ligand to the same receptor (Mercer, 2013). If the first ligand-receptor 
binding event increases the affinity of the receptor to the second ligand, it is positive 
cooperativity; conversely, if the first ligand-receptor binding event decreases the affinity 
of the receptor to the second ligand, it is negative cooperativity (Mercer, 2013). There are 
two forms for cooperativity: allosteric and configurational. Allosteric cooperativity uses a 
conformational change of the receptor after the first binding event to then encourage the 
second binding event. In contrast to this, configuration cooperativity does not use a 
conformational change of the receptor. Instead, the first binding event keeps the second 
ligand in close proximity to the receptor to encourage the second binding event (Figure 
1.1) (Whitty, 2008). Herein, the focus will be configurational cooperativity.  
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Figure 1.1. Allosteric vs. Configurational Cooperativity 
[A] In allosteric cooperativity the receptor undergoes a conformational change after the 
binding of the first ligand to then encourage binding of the second ligand. [B] In 
configurational cooperativity the receptor does not undergo a conformational change. 
Instead, the binding of the first ligand keeps the second ligand in close proximity to the 
receptor to encourage the second binding event. Figure adapted from Whitty 2008. 
 
Positive cooperativity is a tool that can be exploited to manipulate the binding 
affinities of reagents to improve overall accuracy. Examples of deoxyribonucleic acid 
(DNA) reagents that use this principle are tentacle probes (TPs) and cooperative primers 
(CPs), (Satterfield, 2014; Satterfield, West, & Caplan, 2007). The TP and CP reagents are 
composed of two DNA regions, labeled as capture and functional, which are connected 
by a polyethylene glycol (PEG) linker (Figure 1.2). Both the capture and functional 
regions of the TPs/CPs have respective binding locations to target DNA to form DNA 
duplexes.  
 
A) B) 
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Figure 1.2. Schematic of TPs and CPs 
[A] The Tentacle Probe has a hairpin conformation for the functional region (green), 
which keeps the quencher (black circle) near the FAM fluorophore (yellow circle) to 
suppress fluorescence produced by the fluorophore. This functional region is connected 
to a capture region (purple) via a PEG linker (grey box). [B] The Cooperative Primer has 
a short primer around ~12 base pairs for the functional region (green). This region is 
connected to a capture region (purple) via a PEG linker (grey box).  
 
When discussing binding, the concentration of target DNA will be identified as 
Ct; the concentration of TP/CP reagent with both unbound capture and functional regions: 
Cp; with only capture region bound to target DNA: Cp,cap; with only functional region 
bound to target DNA: Cp,func; with both capture and functional region bound to DNA: 
Cp,both.  
Regardless of the differing conformation for the functional region of the TP and 
CP, both experience similar cooperative binding reactions, as modeled in (Figure 1.3). 
Initially, the target DNA strand and TP/CP are free and unbound (Figure 1.3.A). Then 
the first binding event of the TP/CP to the target DNA strand occurs, creating the 
intermediate product (Figure 1.3.B.i-B.ii). This intermediate can be created one of two 
ways, where the functional region binds first (Figure 1.3.B.i) or the capture region binds 
A) 
B) 
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first (Figure 1.3.B.ii). Through cooperativity, the intermediate from B.i increases the 
binding affinity for the capture region and the intermediate from B.ii increases the 
binding affinity for the functional region. This second binding event then creates the final 
product (Figure 1.3.C), assuming no cross-reactions (Cera, 1998). 
 
A) Cp + Ct çè 
B.ii) Cp,cap 
é 
ê  
é 
ê 
B.i) Cp,func 
çè 
 
C) Cp,both 
Figure 1.3. Cooperative binding reactions for TPs and CPs 
[A] The TP/CP is unbound by both the functional and capture regions. The TP/CP 
reagent is free to move throughout the solution with target DNA strands. [Bi] The TP/CP 
functional region can bind to the target DNA strand to form one type of intermediate 
product. [Bii] Conversely, the TP/CP capture region can bind to the target DNA strand to 
form another type of intermediate product. [C] In the Bi intermediate, the functional 
region encourages positive cooperativity for the binding of capture region to create the 
final product. In the Bii intermediate, the capture region encourages positive 
cooperativity for the binding of the functional region to create the final product. The final 
product is both the functional region and capture region of the TP/CP bound to a target 
DNA strand.  
 
The impact of cooperativity on binding affinity can best be assessed through 
mathematical modeling and understanding of collision theory and hybridization 
thermodynamics.  
 
Collision Theory 
Max Trautz, in 1916, and William Cudmore McCullagh Lewis, in 1918, 
developed the kinetic theory of collision. This theory is based on the idea that if every 
collision of molecule A with molecule B resulted in an A–B product, then the collision 
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rate would be equal to the rate of reaction, Eq. (1.1) (Laidler, 1987): 𝑟𝑎𝑡𝑒 = 𝑍!" = 𝜋𝑑!𝑣 𝐴 [𝐵] (1.1) 
where ZAB is the number of collisions for molecules A and B, d is the sum of molecules A 
and B radii, and v is the average velocity of the molecules A and B. However, over the 
years, there have been additions to the simple collision theory. The original theory 
assumes all collisions are effective, which is not always the case, as molecules must not 
only collide to react, but also have mutual orientation and energy (Laidler, 1987). For 
these reasons, the term reaction probability, Pr, was introduced to the collision rate 
equation to account for the likelihood of the products to form, Eq. (1.2) (Laidler, 1987).  𝑟𝑎𝑡𝑒 = 𝑃!𝑍!" = 𝑃!𝜋𝑑!𝑣 𝐴 [𝐵] (1.2) 
Using rate law, the rate of reaction can then be expressed in terms of forward rate 
constant, kf, and concentration of reactants, Eq. (1.3) (Laidler, 1987): 𝑘! 𝐴 𝐵 = 𝑃!𝜋𝑑!𝑣 𝐴 [𝐵] (1.3) 
The rate of the first binding event for TPs/CPs can then be modeled based on Eq. 
1.3. There are two resulting equations to account for the two intermediate products, Cp,cap 
or Cp,func, as shown in Eq. (1.4, 1.5) respectively. 𝑘!,!"# 𝐶! 𝐶! = 𝑃!𝜋𝑑!𝑣 𝐶! [𝐶!] (1.4) 𝑘!,!"#$ 𝐶! 𝐶! = 𝑃!𝜋𝑑!𝑣 𝐶! [𝐶!] (1.5) 
Where kf,cap is the forward rate constant of the capture region binding to the target 
DNA, and kf,func is the forward rate constant of the functional region binding to the target 
DNA. As discussed by Satterfield et al., 2007, the second binding event of TPs/CPs in 
creating the final product Cp,both, follows the same collision theory model as the first 
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binding event; however, it is adjusted to account for the effects of cooperativity. Once 
again, there are two resulting equations to account for the varying forward rate constants, 
dependent on the intermediate reactant, Cp,cap or Cp,func, used to form the Cp,both product, as 
shown in Eq. (1.6, 1.7), respectively. 
𝑘!,!"#$ ! !"#$%&#$!!!!! !! [𝐶!,!"#] = 𝑃!,!""#𝜋𝑑!𝑣 ! !"#$%&#$!!!!! !! 𝐶!,!"#   (1.6) 
𝑘!,!"# ! !"#$%&#$!!!!! !! [𝐶!,!"#$] = 𝑃!,!""#𝜋𝑑!𝑣 ! !"#$%&#$!!!!! !! [𝐶!,!"#$]  (1.7) 
Where l is the x-distance of the linker length, NA is Avogadro’s number, and 
Pr,coop is the cooperative reaction probability. Through the first binding event, the local 
concentration of the second binding event is increased, as the single unbound segment of 
 
the TP/CP is restricted to travel within the spherical space created by the length of the 
PEG linker. This is represented by the ! !"#$%&#$!!!!! !!  term. 
Though collision theory was developed for sphere models, it can be applied to 
DNA binding, as the equations for collision theory are primarily to demonstrate that 
forward rate constants maintain the cooperative ratio differences between the first 
binding and second binding event.  
 
Hybridization Thermodynamics 
There are four reaction equations generated when considering the binding of a 
TP/CP to target DNA. The first two reaction equations, Eq. (1.8, 1.9), correspond to the 
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first binding event, while the last two reaction equations, Eq. (1.10, 1.11), correspond to 
the second binding event.  
𝐶! + 𝐶! !!,!"#!!,!"#  𝐶!,!"# (1.8) 
𝐶! + 𝐶! !!,!"#$!!,!"#$  𝐶!,!"#$ (1.9) 
! !"#$%&#$!!!!! !! +  𝐶!,!"# !!,!"#$!!,!"#$  𝐶!,!"#!  (1.10) 
! !"#$%&#$!!!!! !! +  𝐶!,!"#$  !!,!"#!!,!"#  𝐶!,!"#!  (1.11) 
Where kr,cap is the reverse rate constant of the bound capture region unbinding 
from the target DNA and kr,func is the reverse rate constant of the bound functional region 
unbinding from the target DNA. From the Eq. (1.8-1.11) above, it can be seen there is 
both formation and reverse constants for all reaction equations. This indicates that the 
state of equilibrium is not reached based primarily on completion. Using this information 
of opposing reactions, the net rate change of Cp,cap, Cp,func, and Cp,both concentrations can 
then be calculated, Eq. (1.12-1.14): 
!!!,!"#!" = 𝑘!,!"# 𝐶! 𝐶! − 𝑘!,!"#[𝐶!,!"#]  (1.12) !!!,!"#$!" = 𝑘!,!"#$ 𝐶! 𝐶! − 𝑘!,!"#$[𝐶!,!"#$]  (1.13) 
!!!,!"#!!" = 𝑘!,!"#$ ! !"#$%!"#!!!!! !! 𝐶!,!"# + 𝑘!,!"# ! !"#$%&#$!!!!! !! 𝐶!,!"#$  −(𝑘!,!"#$ + 𝑘!,!"#) 𝐶!,!"#!   
(1.14) 
Where !!!,!"#!"  is the rate of consumption of Cp,cap, !!!,!"#$!"  is the rate of 
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consumption of Cp,func, and 
!!!,!"#!!"  is the rate of consumption of Cp,both. These reactions 
are at equilibrium when the net rate is zero. Using this information, the equilibrium 
constants for the reactions can then be calculated, Eq. (1.15-1.17). The Cp,both equilibrium 
constant is calculated under the assumptions that (1) the functional region of the TP/CP is 
designed to have a weak binding affinity and (2) the capture region of the TP/CP is 
designed to have a strong binding affinity (Satterfield et al., 2007). Through these 
assumptions, the first binding event is favored to be the capture region binding to the 
target DNA. Thus, through the first assumption, the 𝑘!,!"# ! !"#$%&#$!!!!! !! 𝐶!,!"#$  term can 
be set to zero, and through the second assumption, the  𝑘!,!"# term can also be set to zero.  𝑘!"# = !!,!"#!!,!!" = [!!,!"#]!! [!!]  (1.15) 𝑘!"#$ = !!,!"#!!,!"# = [!!,!"#$]!! [!!]   (1.16) 
𝑘!"#! = ! !"#$%&#$!!!!! !! 𝑘!"#$𝑘!"# = [!!"#!]!! [!!] (1.17) 
Where kcap is the equilibrium constant of Cp,cap formation, kfunc is the equilibrium 
constant of Cp,func formation, and kboth is the equilibrium constant of Cp,both.  
Using the standard free energy change for a chemical process at equilibrium and 
Gibbs free energy, Eq. (1.18, 1.19), respectively, the equilibrium constant can then be 
written in terms of thermodynamic properties, Eq. (1.20). Δ𝐺° = −𝑅𝑇𝑙𝑛(𝑘) (1.18) Δ𝐺° = ∆𝐻°− 𝑇∆𝑆° (1.19) 
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𝑘 = 𝑒!(∆!°!!∆!°)/!"  (1.20) 
 Where Δ𝐺° is Gibbs free energy change per mole of reaction, R is the universal 
gas constant, T is absolute temperature of reaction, k is equilibrium constant, ∆𝐻° is 
change in enthalpy, or energy, of a system per mole of reaction, and ∆𝑆° is change in 
entropy, or randomness, of a system per mole of reaction. 
 The change in enthalpy and change in entropy can be approximated using the 
nearest-neighbor model for Watson-Crick base pairs (SantaLucia & Hicks, 2004). 
Through this, ten possible pairing parameters have been defined (Table 1.1). 
Thermodynamic parameters for Watston-Crick nearest neighbor base pairs parameters 
have been further investigated for internal mismatches (Table 1.2). As can be seen in 
both tables, the most energetically favorable pairings are Watson-Crick pairings rather 
than internal mismatches. However, even internal mismatches have the potential to be 
energetically favorable due to a GC or CG nearest neighbor. For example, there is a ∆G° 
difference between the GG/CG mismatch pairing and the GG/CC Watson-Crick pairing 
of 0.73. The GC or CG nearest neighbors are more favorable as they are more stable due 
to the formation of three hydrogen bonds. The Watson-Crick and internal mismatch 
parameters are the foundation for the DNA software database Mfold 
(http://unafold.rna.albany.edu/?q=mfold) (Zuker, 2003) to predict the total ∆H° and ∆S° 
of two sequences. The two-state folding 
(http://unafold.rna.albany.edu/?q=DINAMelt/Two-state-folding)  from Mfold is used to 
calculate the hybridization of the stem structure of the TP while the two-state melting 
(http://unafold.rna.albany.edu/?q=DINAMelt/Two-state-melting) is used for all 
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hybridization properties. The information produced from Mfold can then be plugged into 
Eq. (1.20) with a defined reaction temperature, to determine the equilibrium constant. For 
TPs/CPs, this can be used to calculate the equilibrium constants in the presence of both a 
target and non-target strand to determine the best TP/CP sequence to use.  
 
Table 1.1. Thermodynamic parameters for Watson-Crick nearest neighbor base 
pairs 
Table from SantaLucia & Hicks 2004 and calculated using 1 M NaCl. 
Nearest Neighbor Sequence 
(5’à3’ / 3’à5’) 
∆H°  
(kcal mol-1) 
∆S°  
(cal K mol-1) 
∆G°37 
(kcal mol-1) 
AA/TT -7.6 -21.3 -1.00 
AT/TA -7.2 -20.4 -0.88 
TA/AT -7.2 -21.3 -0.58 
CA/GT -8.5 -22.7 -1.45 
GT/CA -8.4 -22.4 -1.44 
CT/GA -7.8 -21.0 -1.28 
GA/CT -8.2 -22.2 -1.30 
CG/GC -10.6 -27.2 -2.17 
GC/CG -9.8 -24.4 -2.24 
GG/CC -8.0 -19.9 -1.84 
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Table 1.2. Gibbs free energy parameters for internal mismatch of Watson-Crick 
nearest neighbor base pairs 
Table from SantaLucia & Hicks 2004 and calculated using 1 M NaCl. 
  ∆G° 
(kcal mol-1) 
  Y 
Nearest Neighbor Sequence 
(5’à3’ / 3’à5’) 
X A C G T 
GX/CY A 
C 
G 
T 
0.17 
0.47 
-0.52 
- 
0.81 
0.79 
- 
0.98 
-0.25 
- 
-1.11 
-0.59 
- 
0.62 
0.08 
0.45 
CX/GY A 
C 
G 
T 
0.43 
0.79 
0.11 
- 
0.75 
0.70 
- 
0.40 
0.03 
- 
-0.11 
-0.32 
- 
0.62 
-0.47 
-0.12 
AX/TY A 
C 
G 
T 
0.61 
0.77 
0.02 
- 
0.88 
1.22 
- 
0.73 
0.14 
- 
-0.13 
0.07 
- 
0.64 
0.71 
0.69 
TX/AY A 
C 
G 
T 
0.69 
1.33 
0.74 
- 
0.92 
1.05 
- 
0.75 
0.42 
- 
0.44 
0.34 
- 
0.97 
0.43 
0.68 
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CHAPTER 2  
DEVELOPING A RAPID DIAGNOSTIC TEST FOR DETECTING NAVAJO 
NEUROHEPATOPATHY USING TENTACLE PROBES 
Introduction 
Navajo Neurohepatopathy. Navajo neuropathy or neurohepatopathy (NNH) is a 
fatal genetic disorder caused by a R50Q (149G>A) mutation in the MPV17 gene. It is a 
point mutation that changes an arginine to glutamine in the DNA sequence, thus 
impacting the resulting amino acid (Wong et al., 2007). The disease is autosomal 
recessive, as both the mother and father have to be carriers of the mutation in order to 
pass it on to the child (Vu et al., 2001). It affects 1-in-1600 Navajo babies in the 
southwestern region of the U.S., and on average, most patients are diagnosed around 
thirteen months. These patients often don’t live past the age of ten (Vu et al., 2001). The 
main side effects of NNH are characterized by brain damage and liver disease/failure 
(Karadimas et al., 2006). As of now, the only treatment options for this disease are 
dietary control (to prevent hypoglycemia) or liver transplant (Karadimas et al., 2006). 
Despite these treatment options, there is still a significant concern for this disease. 
Evidence shows patients develop neurological problems (i.e. development delay, muscle 
weakness, and reduced sensation) regardless of implementation of one of the treatment 
options (Wong et al., 2007).  
Patients diagnosed with NNH can be grouped into three different categories: (1) 
infantile NNH, (2) childhood NNH, and (3) classic NNH (Vu et al., 2001). These 
categories are based on the age of diagnosis as well as severity of the disease. Patients 
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diagnosed before six months fall within the infantile NNH category. While patients 
diagnosed between one to five-years-old fall within the childhood NNH category. 
Patients of both of these phenotypes experience severe liver dysfunction (hepatopathy), 
and thus, typically have an early death due to liver failure. Though patients do fall within 
these phenotype categories, they are not as common as classic NNH. For classic NNH, 
patients are diagnosed across a spectrum of ages and experience moderate liver 
dysfunction and progressive neurological deterioration (Karadimas et al., 2006).  
Upon exhibiting symptoms, children in the American Southwest region 
(specifically Arizona) seek help from Phoenix Children’s Hospital (PCH). At PCH, 
doctors currently use differential diagnosis in order to detect the root cause of these 
symptoms. Through this process, doctors will run multiple tests in order to distinguish a 
particular disease from other diseases with similar symptoms. In order to diagnose a 
patient with NNH, it was determined that patients must exhibit four of the six symptoms: 
“(1) sensory neuropathy, (2) motor neuropathy, (3) corneal anesthesia, ulcers or scarring, 
(4) liver disease, (5) documented metabolic or immunologic derangement, and (6) central 
nervous system demyelination” (Vu et al., 2001). Following the identification of these 
symptoms, gene sequencing is utilized, as it is a definitive method to diagnosing NNH. 
While this process is conclusive for diagnosing NNH, there are limitations, as it requires 
both time and money. It can take up to several weeks to receive the results of a gene 
sequence. Furthermore, it costs approximately $700 to run a gene sequence. These factors 
create barriers that can directly impact a patient’s quality of life. Thus, there is a need to 
develop a rapid diagnostic tool for PCH that can accurately detect the 149G>A mutation.  
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Specificity and sensitivity. When developing this diagnostic tool, two of the 
requirements determined by PCH were to create a diagnostic that would be at least 95% 
specific and 95% sensitive. Specificity is the ability to identify the proportion of 
negatives that are correctly identified as negatives; the percentage of samples without the 
mutation that are correctly identified as not having the mutation (Balboni et al., 2014). 
While sensitivity is the ability to identify the proportion of positives that are correctly 
identified as positives; the percentage of samples with the mutation that are correctly 
identified as having the mutation (Balboni et al., 2014). A specific test will not give a 
positive for anything that is not the target, and a sensitive test will not overlook a positive 
if the target is there. Thus, a highly specific test has few false positives, and a highly 
sensitive test has few false negatives.  
Types of molecular method detections. There are several molecular methods 
that can be used for point mutation detection. Some of these methods include 
amplification refractory mutation system (ARMS) polymerase chain reaction (PCR), 
restriction fragment length polymorphism (RFLP), molecular beacons (MBs) and TPs. 
Each method was assessed to determine which detection technique would be best for 
fulfilling PCH’s requirements.  
Amplification refractory mutation system. Through ARMS, primers are used 
for the detection of a specific DNA sequence (Whitcombe, Newton, & Little, 1998). For 
a robust ARMS test, two primers are designed. The first primer binds to the region with 
the point mutation while the second primer binds to the same region but without the point 
mutation. Products of ARMS can be detected via gel electrophoresis or in real-time with 
  
15 
SYBR Green (SG). One of the benefits of this method is that is has the potential to detect 
a mutation in genomic DNA (gDNA) (Whitcombe et al., 1998). However, there are 
several disadvantages to this method. Using SG provides a quicker result, however, users 
assume the fluorescence output of SG did correctly detect the target and that no primer-
dimers or other non-target sequences were formed and thus detected by SG – ultimately, 
suggesting a positive diagnosis when it is negative. Furthermore, it can be difficult to 
ensure the design of a primer in which it will thermodynamically favor one sequence with 
the point mutation and not the sequence without the point mutation (see Watson-Crick 
and internal mismatch free energy parameters from Chapter 1). For these reasons, a high 
specificity and sensitivity are not guaranteed when using ARMS as point mutation 
diagnostic.    
Restriction fragment length polymorphism. RFLPs recognize restriction sites 
and create various fragments of DNA after digestion that can then be identified by 
electrophoresis (Mahdieh & Rabbani, 2013). Point mutations have the ability to create or 
destroy restriction sites (Mahdieh & Rabbani, 2013). For these reasons, a change in the 
number/length of fragments can be used to determine a diagnosis. However, a limitation 
with this application is that it requires a mutation to be in a restriction site. In the case of 
NNH, the point mutation does not alter any restriction sites. Even if RFLPs could be used 
to detect NNH, the test requires large amounts of DNA, limits automation possibilities, 
and in some cases, requires the use of the highly toxic ethidium bromide during 
electrophoresis to more easily detect DNA fragments (Mahdieh & Rabbani, 2013).  
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Molecular beacons. MBs are a hairpin structure with a nucleic acid stem loop, 
fluorophore, and quencher. The loop is approximately 15-25 base pairs (bps) long and 
acts as the probe to detect the target sequence (Tyagi & Kramer, 2012). The stem loop is 
approximately 5-7 bps long and serves the function of keeping the fluorophore and 
quencher in close proximity to limit background fluorescence when the probe is unbound 
(Tyagi & Kramer, 2012). When the MB binds to its target, it undergoes a conformational 
change, where the fluorophore and quencher become separated to produce fluorescence.  
There is typically a tradeoff seen with MBs in that an increase in sensitivity 
causes a decrease in specificity (Satterfield, Caplan, & West, 2008). To increase 
specificity, the probe must be designed to have a more positive ∆G for the neighbor 
nucleotides of the point mutation. This more positive ∆G would thermodynamically favor 
the unbound state over the bound state. However, this particular bias can also create a 
more positive ∆G for the probe to the point mutation, since the thermodynamic difference 
between point mutation and no point mutation can be such a small change. This would 
again favor the unbound state over the bound state even in the presence of the point 
mutation and thus increase false negatives (Satterfield et al., 2008). Conversely, to 
increase sensitivity, the probe must be designed to have a more negative ∆G for the point 
mutation, but this can also create a more negative ∆G of the probe to the neighbor 
nucleotides of the point mutation. These more negative ∆G’s would thermodynamically 
favor the bound state over the unbound state even when no point mutation is present and 
thus increase false positives (Satterfield et al., 2008). In the case of a diagnosis, typically, 
false positives are preferred over false negatives. However, false positives can still have 
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dire consequences, as they can lead to negative psychosocial impacts (Brodersen & 
Siersma, 2013; Satterfield et al., 2007).  
In addition to manipulation of the binding affinity to the target, the binding 
affinity of the stem can also be altered. The stem hybridization primarily impacts the 
background fluorescence, regardless of the presence of a target or non-target sequence 
(Satterfield et al., 2007). A longer stem will create a more negative ∆G – increasing the 
affinity of the stem hybridization. This will decrease background fluorescence as most 
MB conformations will be in the stem loop structure and have the fluorescence of the 
fluorophore suppressed by the quencher. However, having a strong stem can also 
negatively impact the binding kinetics of the probe as the thermodynamics can favor the 
stem structure over the probe bound to the target (Satterfield et al., 2007). Conversely, a 
shorter stem will create a more positive ∆G – decreasing the affinity of the stem 
hybridization. This will increase the background fluorescence, as most MB 
conformations will be not be in the hairpin structure, causing the fluorescence to emit due 
to separation of the fluorophore from the quencher. While a weaker stem hybridization 
helps with binding kinetics of the probe to the target, it will also limit the fluorescence 
increase of the system when the probe binds to the target sequence (Satterfield et al., 
2007). Ultimately, all of these design considerations create limitations and can prevent an 
overall high specificity and sensitivity from being obtained. 
  Tentacle probes. TPs are similar to MBs, as there is still a hairpin structure with 
a nucleic acid stem loop, fluorophore, and quencher; however the main difference 
between TPs and MBs is the addition of the capture region to the TPs (Figure 2.1) 
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(Satterfield et al., 2007). When referring to the earlier cooperativity models mentioned in 
the introduction, the functional region of the TP is known as the detection region. The 
capture region binds upward of the target point of interest. Ultimately, this helps with the 
binding kinetics as the probe can be designed to have a more positive ∆G for the neighbor 
nucleotides of the point mutation. Even though this also create a more positive ∆G of the 
probe to the point mutation, this is overcome by the TP due to the capture region holding 
the detection region in closer proximity to the target. When the stem loop unfolds and 
binds to the target region, the fluorophore and quencher are separated, thus causing 
fluorescence (Satterfield et al., 2008). Previous research has demonstrated that TPs (when 
compared to MBs) have the fastest assay time, most sensitive detection limit, and highest 
specificity (Satterfield et al., 2008).  
 
  
19 
 
Figure 2.1. Schematic of TP Binding 
[A] The TP can begin in a closed loop conformation, where the quencher and fluorophore 
are near, thus suppressing fluorescence. [B] The TP can also begin in on open loop 
conformation, where the quencher and fluorophore are separated, emitting fluorescence. 
The ability of the TP to be in either the closed loop or open loop conformation is based 
on the equilibrium constant of the stem loop hybridization, Kstem. There are two pathways 
to create the intermediate product of the TP and target DNA binding. [C] The first 
binding event can be the capture region to the target DNA, Kcap, to form the Ccap 
intermediate.  When bound to the target DNA, the stem loop structure can still switch 
between closed and open conformation. [D] The first binding event can also be the 
detection region to the target DNA, Kdet, to form the Cdet intermediate. [E] Both of these 
intermediates lead to positive cooperative binding to create the Cboth product.  
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TPs can be used in conjunction with real-time polymerase chain reaction (qPCR) 
in order to obtain both low-cost and quick results while maintaining efficacy. With 
qPCR, DNA is amplified through three steps: (1) denaturation, (2) annealing, and (3) 
extension. These three steps make up one cycle, and after each cycle, the DNA is 
doubled. With the TP incorporated in the qPCR, fluorescence can be measured in order to 
generate a graph detailing fluorescence versus cycle number. By including a positive and 
negative control in the experiment the output of the qPCR can be used to determine if a 
sample is positive or negative for a particular disease. Furthermore, including two TPs: 
NNH-negative TP (NNH-N TP) to detect the wild type and NNH-positive TP (NNH-P 
TP) to detect the 149G>A mutation, creates a more robust test. No fluorescence from 
either probe would indicate an inconclusive test and something wrong in the diagnostic, 
fluorescence from only the NNH-P TP would indicate a positive diagnosis, fluorescence 
from only the NNH-N TP would indicate a negative diagnosis, and fluorescence from 
both the NNH-P and NNH-N TPs would indicate a carrier (Figure 2.2). Herein this 
chapter is the verification and assessment of the TP diagnostic.  
 
 
Figure 2.2. Purpose of Dual TPs 
The red light bulb represents the NNH-P TP, while the green light bulb represents the 
NNH-N TP. A darker light bulb represents little to no fluorescence being emitted by the 
TP, while a brighter light bulb represents fluorescence being emitted by the TP. [A] If 
neither TP fluoresces, then the diagnostic is inconclusive and it can be concluded that 
A) B) C) D) 
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some aspect of the test has failed. [B] If only the NNH-P TP fluoresces, then the 
diagnosis can be confirmed as NNH positive. [C] If only the NNH-N TP fluoresces, then 
the diagnosis can be confirmed as NNH negative. [D] If both the NNH-P and NNH-N 
TPs fluoresce, then the diagnosis can be confirmed as positive for NNH carrier.  
 
Materials and Methods 
Oligonucleotide synthesis. Human gDNA was extracted from H1975, a non-
small cell lung cancer, as well as PCH-stored NNH-N and NNH-P formalin-fixed, 
paraffin-embedded (FFPE) liver samples. All human gDNA samples were stored in 
nuclease-free water. Forward (FP) and reverse primer (RP) sequences were designed 
close to the mutation site using OligoAnalyzer 3.1 to give an amplicon of 107 bases. 
Synthetic single-strand DNA (SYN DNA) of 107 bases was designed as positive 
synthetic DNA (P SYN DNA) containing the 149G>A mutation and negative synthetic 
DNA (N SYN DNA) without the 149G>A mutation in wild-type form. Integrated DNA 
Technologies (Skokie, Illinois) synthesized all SYN DNA, which were stored in 
nuclease-free water. The TP sequences were designed to be within the boundary of the 
FP and RP. The NNH-P TP was designed to identify the 149G>A mutation while the 
NNH-N TP was designed to identify the wild-type. TP folding, hybridization, and 
thermodynamic parameters were modeled using Mfold software (Zuker, 2003). These 
thermodynamic parameters were then used to model fluorescence, and TPs were chosen 
based on >50% and <1% fluorescence in target and non-target sequences, respectively. 
BioSearch (Petaluma, CA) synthesized all TPs, which were suspended in 10 mM Tris, 1 
mM EDTA, pH 8.0 (see Table 2.1 for primer, synthetic DNA, and TP sequences). 
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Table 2.1. Primer, synthetic DNA, and TP sequences for NNH diagnostic 
Name 
Sequence 
5’ à 3’ 
FP AGAGGCGGGGTCTGCAG 
RP TGAGTCCACTGAAGCCCTGTTG 
N SYN DNA 
AGAGGCGGGGTCTGCAGGAACACCAGAGAGGCCGGACTCTG
ACCATGGTGTCCCTGGGCTGTGGCTTTGTGGTAAGTTCTCCCT
CAACAGGGCTTCAGTGGACTCA 
P SYN DNA 
AGAGGCGGGGTCTGCAGGAACACCAGAGAGGCCAGACTCTG
ACCATGGTGTCCCTGGGCTGTGGCTTTGTGGTAAGTTCTCCCT
CAACAGGGCTTCAGTGGACTCA 
NNH-N TP 
[FAM]CGGAGTCCCGGACTCCG[BHQ-1][SPACER 
18]GTGTCCCTGGGCT 
NNH-P TP 
[FAM]CCGGAGTCTGAGGCCAGACTCCGG[BHQ-1][SPACER 
18]GTGTCCCTGGGCTGTGGCTTTG 
 
Primer design and optimization. To determine optimal primer annealing 
conditions, 8 samples of 50 µL were diluted with water to have 10 ng/µL of H1975 DNA, 
1 µM FP, 1 µM RP, and 1X GoTaq Green Master Mix (Promega). Samples were loaded 
in a C100 Touch Thermal Cycler. Cycling conditions were an initial denaturation of 95°C 
for 30 s, annealing temperature gradient of 50°C-70°C for 20 s, and extension of 72°C for 
30 s for a total of 25 cycles. Gel electrophoresis using 1X TAE buffer was then 
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performed on the samples using a 1% agarose gel for 40 min at 110 V with a 1 Kb plus 
DNA ladder (ThermoFisher) and 100 bp DNA Ladder (ThermoFisher) for reference. 
Optimal annealing temperature was determined to be 66°C.  
NNH-N and NN-P TP design and optimization. NNH-N and NNH-P TPs were 
first designed in silico using calculations of the enthalpy and entropy hybridization of 
both the detection and capture regions to target and non-target strands. Using a set 
reaction temperature of 55°C, equilibrium constants were then calculated. These 
equilibrium constants were then used to calculate the fluorescence of the TP, Eq. (2.1), 
derived by Satterfield: 
𝐹 =∝ !!"#$! ! !"#$%&#$!!!!! !! !!"#$!!"#!!"#! !!!!"#!!!!!!!"#!   (2.1) 
Where F is the fluorescence and T0 is the initial target concentration and P0. In 
Satterfield et al. 2007, the equation also includes a β and γ term. The β term represents 
the fluorescence when the TP is unbound and closed in stem loop structure, and the γ 
term represents the fluorescence when the TP is unbound and open from stem loop 
structure. These terms are not included as both β and γ fluorescence are used to calculate 
the background fluorescence, which should be the same in the presence of both a target 
and non-target sequence. Furthermore, the equilibrium constant of the stem loop structure 
can be used to ensure there is little to no fluorescence occurring for the γ term. The best 
TPs were determined to be >50% fluorescence in presence of target sequence and <0.1% 
fluorescence in presence of non-target sequence. 
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To determine optimal TP annealing conditions, 4 samples (P SYN DNA + NNH-
P TP, N SYN DNA + NNH-P TP, P SYN DNA + NNH-N TP, and N SYN DNA + NNH-
N TP) of 20 µL were diluted with water to have 10 ng/µL of specified pre-amplified 
synthetic DNA, 1X ThermoPol Reaction Buffer (NEB), and 0.1 µM specified TP. 
Samples were loaded in a Roche LightCycler 480. A melting curve was performed 
starting at 95°C with a 2 min hold and 1°C decrease until 37°C. Optimal annealing 
temperatures of the NNH-P TP and NNH-N TP was determined to be 55°C and 44°C, 
respectively.  
NNH-N and NNH-P TP synthetic DNA verification. To assess NNH-N TP 
efficacy with synthetic DNA, 2 samples (N SYN DNA + NNH-N TP and P SYN DNA + 
NNH-N TP) were prepared to be 400 µL each diluted with water to have 1 pg/µL of 
specified SYN DNA, 1X GoTaq Colorless Master Mix (Promega), 1 µM FP, 1 µM RP, 
and 0.1 µM NNH-N TP. Two controls (N SYN DNA + SG and P SYN DNA + SG) were 
prepared to be 60 µL each diluted with water to have 1 pg/µL of specified synthetic 
DNA, 1 µM FP, 1 µM RP, and 1X SYBR Green I (Roche). Twenty-µL samples sizes 
were pipetted from each master mix sample into a 96-well plate; there were 20 replicates 
for each TP sample and 3 replicates for each SG sample. The 96-well plate was loaded in 
a Roche LightCycler 480. Cycling conditions were an initial denaturation of 95°C for 30 
s, primer annealing of 66°C for 20 s, extension of 72°C for 30 s, denaturation of 95°C for 
30 s, and TP annealing of 44°C for 2 min for a total of 25 repeats. A fluorescence 
measurement was made after the extension phase and after the TP annealing phase. Data 
was exported to excel and split into fluorescence values specific to SG and TP. The first 
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derivative of fluorescence for the TP was then plotted versus cycle number. 
To assess NNH-P TP efficacy with synthetic DNA, 2 samples (N SYN DNA + 
NNH-P TP and P SYN DNA + NNH-P TP) were prepared to be 400 µL each diluted with 
water to have 1 pg/µL of specified synthetic DNA, 1X GoTaq Colorless Master Mix, 1 
µM FP, 1 µM RP, and 0.1 µM NNH-P TP. Two controls (N SYN DNA + SG and P SYN 
DNA + SG) were prepared to be 40 µL each diluted with water to have 1 pg/µL of 
specified synthetic DNA, 1 µM FP, 1 µM RP, and 1X SG. Twenty-µL samples sizes were 
pipetted from each master mix sample into a 96-well plate; there were 20 replicates for 
each TP sample and 2 replicates for each SG sample. The 96-well plate was loaded in a 
Roche LightCycler 480. Cycling conditions were an initial denaturation of 95°C for 30 s, 
primer annealing of 66°C for 20 s, extension of 72°C for 30 s, denaturation of 95°C for 
30 s, and TP annealing of 55°C for 2 min for a total of 25 repeats. A fluorescence 
measurement was made after the extension phase and after the TP annealing phase. Data 
was exported to excel and split into fluorescence values specific to SG and TP. The first 
derivative of fluorescence for the TP was then plotted versus cycle number. 
NNH-N and NNH-P TP genomic DNA verification. Five patient gDNA 
samples (patient 01 negative gDNA (N gDNA01), N gDNA02, N gDNA03, N gDNA04, 
and patient 01 positive gDNA (P gDNA01)) were prepared to be 100 µL diluted with 
water to have 10 ng/µL of specified DNA, 1 µM FP, 1 µM RP, and 1X GoTaq Green 
Master Mix. Fifty-µL samples sizes were pipetted from each master mix sample into a 
0.2 mL PCR tube; there were 2 replicates per sample. Samples were loaded in a C100 
Touch Thermal Cycler. Cycling conditions were an initial denaturation of 95°C for 30 s, 
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annealing of 66°C for 20 s, and extension of 72°C for 30 s for a total of 25 repeats. 
Replicates were then combined in the same PCR tube to perform PCR purification kit 
(QIAquick). DNA was eluted in nuclease-free water.  
To assess NNH-N and NNH-P TP efficacy with gDNA, 14 samples (N gDNA01 
+ NNH-N TP, N gDNA02 + NNH-N TP, N gDNA03 + NNH-N TP, N gDNA04 + NNH-
N TP, positive genomic DNA 01 P gDNA01 + NNH-N TP, N SYN + NNH-N TP (+ 
control), P SYN + NNH-N TP (- control), N gDNA01 + NNH-P TP, N gDNA02 + NNH-
P TP, N gDNA03 + NNH-P TP, N gDNA04 + NNH-P TP, P gDNA01 + NNH-P TP, N 
SYN + NNH-P TP (- control), and P SYN + NNH-P TP (+ control)), were prepared to be 
100 µL each diluted with water to have 1 pg/µL of specified pre-amplified gDNA or SYN 
DNA, 1X GoTaq Colorless Master Mix, 1 µM FP, 1 µM RP, and 0.1 µM specified TP. 
Seven controls (N gDNA01 + SG, N gDNA02 + SG, N gDNA03 + SG, N gDNA04 + 
SG, P gDNA + SG, N SYN + SG, and P SYN + SG) were prepared to be 40 µL each 
diluted with water to have 1 pg/µL of specified SYN DNA, 1 µM FP, 1 µM RP, and 1X 
SG. Twenty-µL samples sizes were pipetted from each master mix sample into a 96-well 
plate; there were 5 replicates for each type of TP sample and 2 replicates for each SG 
sample. The 96-well plate was loaded in a Roche LightCycler 480. Cycling conditions 
were an initial denaturation of 95°C for 30 s, primer annealing of 66°C for 20 s, 
extension of 72°C for 30 s, denaturation of 95°C for 30 s, TP annealing of 44°C for 2 
min, denaturation of 95°C for 30 s, TP annealing of 55°C for 2 min for a total of 25 
repeats. A fluorescence measurement was made after the extension phase and after each 
TP annealing phase. Data was exported to excel and split into fluorescence values 
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specific to SG, NNH-N TP, and NNH-P TP. The first derivative of fluorescence was 
averaged for both the NNH-N TP and NNH-P TP and plotted versus cycle number. 
Simulated synthetic DNA carrier. To assess potential to identify an NNH 
carrier, 6 samples (N SYN DNA + NNH-N TP, P SYN DNA + NNH-N TP, N SYN 
DNA:P SYN DNA + NNH-N TP, N SYN DNA + NNH-P TP, P SYN DNA + NNH-P 
TP, and N SYN DNA:P SYN DNA + NNH-P TP) were prepared to be 60 µL each 
diluted with water to have 1 pg/µL of specified SYN DNA (N SYN DNA:P SYN DNA 
was prepared in a 1:1 ratio), 1X GoTaq Colorless Master Mix, 1 µM FP, 1 µM RP, and 
0.1 µM specified TP. Three controls (N SYN DNA + SG, P SYN DNA + SG, and N 
SYN DNA:P SYN DNA + SG) were prepared to be 40 µL each diluted with water to 
have 1 pg/µL of specified SYN DNA, 1 µM FP, 1 µM RP, and 1X SG. Twenty-µL 
samples sizes were pipetted from each master mix sample into a 96-well plate; there were 
3 replicates for each TP sample and 2 replicates for each SG sample. The 96-well plate 
was loaded in a Roche LightCycler 480. Cycling conditions were an initial denaturation 
of 95°C for 30 s, primer annealing of 66°C for 20 s, extension of 72°C for 30 s, 
denaturation of 95°C for 30 s, TP annealing of 44°C for 2 min, denaturation of 95°C for 
30 s, TP annealing of 55°C for 2 min for a total of 25 repeats. A fluorescence 
measurement was made after the extension phase and after each TP annealing phase. 
Data was exported to excel and split into fluorescence values specific to SG, NNH-N TP, 
and NNH-P TP. The first derivative of fluorescence was averaged for both the NNH-N 
TP and NNH-P TP and plotted versus cycle number. 
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Results and Discussion 
Primer verification. Results from the temperature annealing gradient (Figure 
2.3) indicate that for every temperature there is a primary band just barely above 100 bps, 
which is close to the expected 107 bp product. At temperatures 66°C and above (Figure 
2.3, lanes 2-4), there are no additional by-products created, while there are larger by-
products created at temperatures 62.5°C and below (Figure 2.3, lanes 5-9). Ultimately, 
the bands for 66°C – 70°C show the primers are specific to the target amplicon of interest 
even when exposed to complex gDNA. The annealing temperature 66°C was chosen as 
the optimal temperature, as it produces the most product, indicated by the thicker and 
darker band (Figure 2.3, lane 4).  
 
 
Figure 2.3. Annealing temperature gradient for NNH primers of gDNA 
Lanes 1 and 10 are DNA ladders. Lane 1 is 100 bp DNA ladder and lane 10 is a 1 Kb 
plus DNA ladder. Lanes 2-9 are temperatures used for the annealing temperature 
gradient. Lane 2 is 70°C3, lane 3: 68.5°C, lane 4: 66°C, lane 5: 62.5°C, lane 6: 57.9°C, 
lane 7: 54.5°C, lane 8: 51.8°C, and lane 9: 50°C. Results suggest 66°C as the best primer 
annealing temperature in the presence of genomic DNA.  
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NNH-N and NNH-P TP synthetic DNA verification. SG showed all samples 
amplified efficiently (results not shown). Figure 2.4 shows results for NNH-N TP while 
Figure 2.5 shows results for NNH-P TP. From both graphs, it can be seen that there is a 
significant difference in fluorescence between positive and negative controls. Thus 
verifying both the NNH-N and NNH-P TPs can correctly differentiate between samples 
with and without the 149G>A mutation. Furthermore, the results indicate both the NNH-
N and NNH-P TPs have 100% sensitivity and 100% specificity in the presence of 
synthetic DNA. 
 
 
Figure 2.4. NNH-N TP synthetic DNA verification 
Main graph shows derivative of NNH-N TP fluorescence versus cycle number. Top right 
graph shows raw fluorescence values. Raw fluorescence across all replicates was adjusted 
to begin at the most minimum fluorescence. The dark red is N SYN DNA and the cyan is 
P SYN DNA.  Results of 20 replicates per sample shows 100% specificity and 100% 
sensitivity. NNH-N TP capture and detection region is bound for the N SYN DNA while 
only the capture region is bound for the P SYN DNA. 
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Figure 2.5. NNH-P TP synthetic DNA verification 
Main graph shows derivative of NNH-P TP fluorescence versus cycle number. Top right 
graph shows raw fluorescence values. Raw fluorescence across all replicates was adjusted 
to begin at the most minimum fluorescence. The dark red is N SYN DNA and the cyan is 
P SYN DNA.  Results of 20 replicates per sample shows 100% specificity and 100% 
sensitivity. NNH-P TP capture and detection region is bound for the P SYN DNA while 
only the capture region is bound for the N SYN DNA. 
 
NNH-N and NNH-P TP genomic DNA verificaiton. SG showed all samples 
amplified efficiently (results not shown). Figure 2.6 shows results for NNH-N TP while 
Figure 2.7 shows results for NNH-P TP. Genomic DNA samples required pre-
amplification prior to the introduction of a TP. Complex gDNA seemed to impact the 
specificity of the TP (results not shown). This similar type of result was obtained by 
Satterfield when evaluating CPs, which uses similar binding kinetics (Satterfield, 2014).  
It would have been preferred to not use pre-amplified gDNA, as this would have further  
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reduced run-time for the diagnostic and limited potential contaminations; however, pre-
amplification is a necessary step to create more specificty in the diagnostic. From both 
graphs, it can be seen that there is a significant difference in fluorescence between 
positive and negative controls as well as positive and negative patient samples. Thus 
further verifying both the NNH-N and NNH-P TPs can correctly differentiate between 
samples with and without the 149G>A mutation. Furthermore, the results indicate both 
the NNH-N and NNH-P TPs nearly have 100% sensitivity and 100% specificity in the 
presence of patient gDNA. This is based on a limited number of available positive patient 
samples though so these numbers may decrease as more samples are tested.  
 
 
Figure 2.6. NNH-N TP genomic DNA verification 
Main graph shows derivative of NNH-N TP fluorescence versus cycle number. Top right 
graph shows raw fluorescence values. Raw fluorescence across all replicates was adjusted 
to begin at the most minimum fluorescence. The dark blue, orange, yellow, purple, green, 
cyan, and dark blue lines represent NNH-N FFPE patient 1 tissue sample, NNH-N FFPE 
LINKER	
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patient 2 tissue sample, NNH-N FFPE patient 3 tissue sample, NNH-N FFPE patient 4 
tissue sample, NNH-P FFPE patient 1 tissue sample, P SYN DNA, and N SYN DNA, 
respectively. Samples were run with 5 replicates and average of those replicates are 
displayed in the first derivate and raw fluorescence graphs. Results of 4 negative patient 
replicates and 1 positive patient replicate suggests nearly 100% specificity and 100% 
sensitivity. NNH-N TP capture and detection region is bound for the NNH-N patient 
samples and N SYN DNA while only the capture region is bound for the NNH-P patient 
sample and P SYN DNA. 
 
 
Figure 2.7. NNH-P TP genomic DNA verification 
Main graph shows derivative of NNH-P TP fluorescence versus cycle number. Top right 
graph shows raw fluorescence values. Raw fluorescence across all replicates was adjusted 
to begin at the most minimum fluorescence. The dark blue, orange, yellow, purple, green, 
cyan, and dark blue lines represent NNH-N FFPE patient 1 tissue sample, NNH-N FFPE 
patient 2 tissue sample, NNH-N FFPE patient 3 tissue sample, NNH-N FFPE patient 4 
tissue sample, NNH-P FFPE patient 1 tissue sample, P SYN DNA, and N SYN DNA, 
respectively. Samples were run with 5 replicates and average of those replicates are 
displayed in the first derivate and raw fluorescence graphs. Results of 4 negative patient 
replicates and 1 positive patient replicate suggests nearly 100% specificity and 100% 
sensitivity. NNH-P TP capture and detection region is bound for the NNH-P patient 
sample and P SYN DNA while only the capture region is bound for the NNH-N patient 
samples and N SYN DNA. 
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Assessment of the raw SG results from the genomic DNA data (data not shown), 
indicated there was amplification of DNA occurring at the 72°C extension and potentially 
44°C annealing, 55°C annealing, or both. Though Taq polymerase works optimally at 
72°C, it can still work at lower temperatures, just less efficiently. Using excel, a 
mathematical model (results not shown) was created to try and match the raw SG results 
and determine at which temperatures the DNA was amplifying during qPCR. Results 
indicated amplification of DNA occurred at 72°C, 44°C, and 55°C. Prior to this 
assessment, fluorescence results were reported as being for cycles 1-25, however, with 
this new information, fluorescence was reported for cycles 1-75. This impacted the 
derivative as the change in fluorescence was divided by a difference of 3 cycles instead 
of 1 cycle. This primarily impacted the maximum fluorescence obtained but not the 
difference in fluorescence between the positive and negative samples as both samples 
were decreased by the same magnitude. Though overall fluorescence is minimal (<0.3), it 
is relative and can change with every LightCycler machine.  
To verify the output products of qPCR, 2 samples (N SYN DNA + SG and P SYN 
DNA + SG) were prepared to be 20 µL each diluted with water to have 1 pg/µL of 
specified synthetic DNA, 1 µM FP, 1 µM RP, and 1X SG. Twenty-µL of each sample 
was pipetted into a 96-well plate, which was loaded in a Roche LightCycler 480. Cycling 
conditions were an initial denaturation of 95°C for 30 s, primer annealing of 66°C for 20 
s, extension of 72°C for 30 s, denaturation of 95°C for 30 s, TP annealing of 44°C for 2 
min, denaturation of 95°C for 30 s, TP annealing of 55°C for 2 min for a total of 25 
repeats. A fluorescence measurement was made after the extension phase and after each 
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TP annealing phase. Following qPCR, 12 µL master samples were created with 10 µL of 
each sample from the 96-well plate combined with 6X Gel Loading Dye diluted to 1X. 
The 12 µL samples were then run with a 1 Kb plus DNA ladder and 100 bp DNA ladder 
at 110V for 40 min on a 1% agarose gel prepared with 1X TAE buffer (Figure 2.8). 
Results show a large smear for both samples (Figure 2.8, lanes 2 and 3), which is most 
likely due to the large amount of sample loaded. Furthermore, results primarily show the 
amplified band of interest with no additional by-products despite indicated amplification 
from qPCR SG results.  
 
 
Figure 2.8. Amplified products following qPCR with three annealing steps 
Lanes 1 and 4 are DNA ladders. Lane 1 is 1 Kb plus DNA ladder and lane 4 is a 100 bp 
DNA ladder. Lane 2 is the results of the amplified products from P SYN DNA. Lane 3 is 
the results of the amplified products from N SYN DNA. 
 
Simulated synthetic NNH carrier. SG showed all samples amplified efficiently 
(results not shown). Figure 2.9 shows results for both NNH-N TP and NNH-P TP. Both  
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TPs will equally bind to both target and non-target sequences due to their capture regions. 
However, only the TPs bound to the target sequence by the capture region will fluoresce. 
Since this is only half of the TPs, only half the fluorescence will be produced. From the 
graph, it can be seen that this theory does align with the results. The NNH-N and NNH-P 
TPs have the ability to not only identify homozygous individuals but also heterozygous. 
Thus providing the potential to develop the diagnostic into a screening tool.  
 
 
Figure 2.9. NNH-N and NNH-P TPs synthetic simulated DNA carrier verification 
First derivative of NNH-N and NNH-P TP fluorescence versus cycle number. Raw 
fluorescence across all replicates was adjusted to begin at the most minimum 
fluorescence with respect to TP assessed. The orange, dark blue, and yellow lines 
represent N SYN DNA, P SYN DNA, and 1:1 ration of N SYN DNA:PSYN DNA, 
respectively. The dashed lines represent the NNH-N TP, and the solid lines represent the 
NNH-P TP. Samples were run with 3 replicates and average of those replicates are 
displayed in the first derivate. Results suggest an ability to detect NNH carriers. For 
carriers, the NNH TPs capture regions can equally bind to either N SYN DNA or P SYN 
DNA, however, the detection region will only bind for the corresponding target DNA, 
producing half the fluorescence.  
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Conclusion 
TPs have been developed as a diagnostic tool for NNH. The NNH-N TP was 
designed to detect a wild-type sequence, without the 149G>A mutation, while the NNH-
P TP was designed to detect the 149G>A mutation. Verification of the TPs was 
performed with P SYN DNA and N SYN DNA as well as NNH-N patient FFPE liver 
gDNA and NNH-P patient FFPE liver gDNA. Results suggest 100% specificity and 
100% sensitivity for SYN DNA as well as patient gDNA. The specificity and sensitivity 
may decrease, as the number of positive patient samples available increases.  
As more NNH-P patient samples become available, they will be tested through 
this diagnostic to build the sample size and continue verification of the sensitivity and 
specificity of the TP diagnostic test. Future work will also look at beginning clinical trials 
for detecting carriers of NNH, as this type of sample is more readily available than the 
NNH-P sample type. 
In the meantime, melting curves will be re-created for the NNH-N and NNH-P TP 
optimization tests. The original melting curves show very little difference in fluorescence 
between the P SYN and N SYN data. After determining the greatest change in 
fluorescence of the probes occurs around cycle 6, a calculation was performed to 
determine the number of copies of DNA at that cycle number based on 1 pg/µL initial 
DNA. This copy number was then converted to a concentration for the melting curves. 
Previously, the melting curves were performed with 10 ng/µL of SYN DNA, however at 
this concentration, the fluorescent difference between the NNH-N and NNH-P TPs was 
minimal. The melting curves will be re-run with an initial concentration of 65 pg/µL to 
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obtain the greatest difference in fluorescence. 
A contamination experiment will also be conducted to determine the specificity of 
the probes. P SYN DNA will range form 100% to 0.01% contamination in N SYN DNA 
and run with NNH-P TP. Similarly, N SYN DNA will range form 100% to 0.01% 
contamination in P SYN DNA but be run with NNH-N TP. This will help to validate the 
specificity of the probes and help develop the robustness of the test.  
This thesis body of work has focused on the role of amplification and detection of 
the NNH diagnostic. Assuming no automation and over exaggerating of preparation 
times, it will take approximately 7 hours of technician time to prepare the diagnostic 
(from pre-amplification to running the samples with the TP) and approximately 12 hours 
for a total run-time. For these reasons, it estimated that the diagnostic could have an 
approximate turn-around time of 48 hours from the time the patient enters PCH, 
compared to the current 3-4 week timeframe. Furthermore, most of the costs are for the 
amplification and detection role of the NNH diagnostic. This cost breakdown is shown in 
Table 2.2. This cost is created for one run and is inclusive of a positive control, negative 
control, and one patient sample. Each of these samples is run under the assumption of 3 
replicates each for the NNH-N TP and NNH-P TP as well as 3 replicates each for SG. 
The most expensive cost is the clinical technician labor, which was estimated at 
$24.48/hr, as based on the 2016 median pay outlined by Bureau of Labor Statistics 
(Bureau of Labor Statistics, 2018). Because the cost of the item purchased does not 
include shipping or tax and because the cost breakdown does not include sample 
collection and extraction, the overall cost of the diagnostic was estimated to be 
  
38 
approximately $250 for the in-house diagnostic, compared to the current $700 for 
outsourcing the diagnostic.  
Future work could continue to decrease the time and cost for this diagnostic by 
introducing automated processes, finding quicker methods for pre-amplification of 
gDNA, and assessing if a 2 min annealing time is needed per TP. Even if a 2 min 
annealing step is required, new TPs could be designed to have the same annealing 
temperature to reduce on the number of annealing steps required and thus overall time.  
 This diagnostic has the potential to be life-saving in cases of NNH. Thus far, it 
has shown to have nearly 100% specificity and 100% sensitivity in the presence of 
positive and negative patient FFPE liver gDNA samples. When evaluating the future 
sample type: blood, the use of a QIAamp DNA Blood Mini Kit produces, at minimum, a 
400 ng yield of DNA from a 20 µL whole blood sample (equivalent to a drop of blood) 
(Qiagen, 2018). This yield is more than enough to perform the pre-amplification of 
gDNA since this requires anywhere from 50 – 250 ng of DNA for a 50 µL reaction 
(Barrick Lab, 2017). Ultimately, the low volume of blood, low cost, quick turnaround 
time, and high specificity and sensitivity makes the NNH TP diagnostic a favorable 
molecular method for use by PCH.  
This diagnostic creates a translatable protocol for any point mutation detection. 
Further investigation of the diagnostic has demonstrated its potential as a screening tool, 
as the probes are capable of detecting a simulated SYN DNA carrier. Ultimately, early 
diagnosis and screening can help with genetic counseling and ensuring families have the 
information needed to understand the genetic disorder and make necessary decisions. 
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Table 2.2. Cost breakdown for amplification and detection role of NNH diagnostic 
Cost breakdown is inclusive for one positive control, one negative control, and one 
patient sample with 3 replicates each of the NNH-N TP and NNH-P TP as well as 3 
replicates of SG. Cost of items does not include shipping or tax.  
Item 
Quantity 
Purchased 
Cost  
Quantity 
Used 
Cost per Test 
FP (1 µM) 6951 µL $17.00 2.3 µL $0.008 
RP (1 µM) 6968 µL $22.00 2.3 µL $0.01 
P SYN DNA (4 nmol) 132525.6 µL $85.60 0.0018 µL $1.16E-06 
N SYN DNA (4 nmol) 132589.6 µL $85.60 0.0018 µL $1.16E-06 
GoTaq Green 2X Master 
Mix (1,000 rxns) 
25000 µL $379.00 75.0 µL $1.14 
GoTaq Colorless Master 
Mix (1,000 rxns) 
25000 µL $379.00 90.0 µL $1.36 
NNH-N TP (200 nmol) 2000 µL $490.00 0.18 µL $0.04 
NNH-P TP (200 nmol) 2000 µL $490.00 0.18 µL $0.04 
SYBR Green I (500 rxns) 5000 µL $391.00 90.0 µL $7.04 
PCR Purification Kit  250 rxns $550.00 3 rxns $6.60 
LightCycler480 
Multiwell Plate 96 
50 plates $467.74 30 wells $2.92 
Consumables - - - $10 
Technician Labor - $24.48/hr 7 hr $153.64 
    Total: $182.81 
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CHAPTER 3  
AMPLFICIATION OF BOWTIE-BARCODED ORIGAMI WITH CAPTURED TCRΑ 
AND TCRΒ USING COOPERATIVE PRIMERS 
Introduction 
The adaptive immune system has a broad antigen receptor repertoire as well as its 
specificity (Attaf, Huseby, & Sewell, 2015). It is comprised of B and T cells, where each 
cell has its own receptor for recognizing an antigen. The receptor on the T cell is known 
as the T cell receptor (TCR). It is heterodimer, as it is composed of two chains; there are 
two sets of chains used to form the TCR: (1) α and β chains or (2) δ and γ chains (Attaf et 
al., 2015). The αβ TCRs are more common than δγ, comprising around 90% of 
circulating T cells, therefore they are the primary focus of this research (Mirzaei, Mirzaei, 
Lee, Hadjati, & Till, 2016).  
 It has been previously suggested that the large, complex repertoire for αβ TCRs is 
dependent on genetic factors; one impact stemming from these genetic factors is V(D)J 
recombination (Attaf et al., 2015). Each chain has a V, J, and C region, and the β chain 
has an additional D region (Davis & Bjorkman, 1988). There are multiple V(D)J gene 
segments, and these gene segments are randomly assembled next to a specific C region to 
create various combinations for the α and β chains. Further pairing of the α chain with the 
β chain to form the TCR develops an even greater number of combinations (Figure 3.1). 
Knowing the assignment of the particular α and β chain pairing can help to identify TCR 
specificity, thus leading to development of potential diagnostic biomarkers as well as 
immunotherapy options (Mirzaei et al., 2016; Redmond, Poran, & Elemento, 2016).  
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Figure 3.1. TCR V(D)J Recombination with α and β Chains 
The alpha chain (shown in orange) can be made up through a variety of V and J 
combinations while the beta chain (shown in purple) can be made up through a variety of 
V, D, and J combinations. The combination of the alpha and beta chain creates large 
repertoire for the TCR. Figure adapted from OpenStax College “Illustration from 
Anatomy & Physiology Connexions Web site”. 
 
Specificity of TCR is dependent on the pairing of the α and β chains; therefore, 
there is a need to develop a system that identifies both the α and β chains gene sequences 
of a single-cell. To create a high-throughput system, this further needs to identify α and β 
chains of a single-cell but within a heterogeneous cell population. Drs. Louis Schoettle 
and Joseph Blattman have developed a solution in which a nanostructure is transfected 
into individual cells of a heterogeneous cell population to capture and protect α and β 
messenger ribonucleic acid (mRNA). In the nanostructure is a bowtie-barcoded origami 
strand (Figure 3.2). The 12 bp barcodes (BCs) on the left and right side of a single 
origami strand are complimentary and unique to a single origami strand. This BC linkage 
provides a system for pairing α and β mRNA derived from a single-cell (Figure 3.3). 
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Figure 3.2. Bowtie-barcoded origami strand pre-mRNA capture 
Diagram from Dr. Louis Schoettle. The BC on the left of the strand matches the BC on 
the right. Each origami strand has its own unique BC.  
 
 
Figure 3.3. Bowtie-barcoded origami strand with captured mRNA 
Diagram from Dr. Louis Schoettle. Both the α and β mRNA strands are captured from 
within the same cell.   
 
Following intracellular capture, the cell population is lysed to obtain the bowtie-
barcoded origami strand with the captured mRNA. Reverse transcription (RT) is then 
performed on the strand, to elongate the bowtie-barcoded origami strand with 
complementary DNA (cDNA) (Figure 3.4). 
 
Figure 3.4. RT of origami captured α and β mRNA 
Diagram from Dr. Louis Schoettle. The bowtie-barcoded origami strand is further 
elongated to include the α and β mRNA strands. These mRNA strands are tied to the 
same BC so it is known what pairing of α and β mRNA makes up the TCR of a single-
cell. 
 
Using PCR, this cDNA is then amplified for sequencing. The Vα primer binds to 
the left side of the bowtie-barcoded origami strand while the Vβ primer binds to the right 
side (Figure 3.5). The products generated from the Vα and Vβ primers (Figure 3.6) are 
then used as the template for the X and Y primers, respectively (Figure 3.7).  
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Figure 3.5. Vα and Vβ primer anneal and extension 
Diagram from Dr. Louis Schoettle. The Vα and Vβ primers bind to the ends of the 
bowtie-barcoded origami to create a copy of the α and β gene segments with the BCs. 
The elongation of the primers ends just before the zigzags, as this is the location of a 
linker.   
 
 
Figure 3.6. Products generated following PCR of Vα and Vβ primers 
Diagram from Dr. Louis Schoettle. These are the products in the solution following Vα 
and Vβ elongation. The Vα and Vβ products must first be generated prior to elongation 
with the X and Y primers. 
 
 
Figure 3.7. X and Y primers theoretical anneal and extension 
Diagram from Dr. Louis Schoettle. The X and Y primers bind to the ends of the Vα and 
Vβ products to create and additional copy of the α and β gene segments with the BCs. 
 
When the PCR of the bowtie-barcoded origami template is performed using only 
the left-side primers (Vα + X), the expected left-product is produced (Figure 3.8, lane 2). 
Similarly, when using only the right-side primers (Vβ + Y), the expected right-product is 
produced (Figure 3.8, lane 3). However, when PCR of the bowtie-barcoded origami 
template is performed with the left-side primers and right-side primers together (Vα + X 
+ Vβ + Y), the two bands of the expected products are not produced (Figure 3.8, lane 4). 
This is due to the symmetry within the bowtie-barcoded origami template. The X primer 
can bind to either the Vα product or the right-side of the bowtie-barcoded origami 
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template, and the Y primer can bind to either the Vβ product or the left-side of the 
bowtie-barcoded origami template (Figure 3.9). As PCR cycles continue, conditions 
favor the smaller product (Figure 3.10). Because of this amplification, the α and the β 
V(D)J segments cannot be associated with a BC and thus paired. The left- and right-side 
PCR of the bowtie-barcoded origami template cannot be performed separately, as each 
origami will have its own BC and separation of the primers will provide data for only the 
α or β chain.  
 
 
Figure 3.8. Amplified products using Vα, Vβ, X, and Y primers  
RT, PCR, and gel electrophoresis produced by Dr. Louis Schoettle. Lane 1 is 100 bp 
DNA ladder. Lane 2 is the result of the amplified products from Vα + X primers. Lane 3 
is the result of the amplified products from Vβ + Y primers. Lane 4 is the result of the 
amplified products from Vα + X + Vβ + Y primers.  
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Figure 3.9. Two binding locations for X and Y primers 
Diagram adapted from Dr. Louis Schoettle. The X and Y primers have two potential 
binding locations. The X primer can either bind to the Vα product or the right side of the 
origami product. The Y primer can either bind to the Vβ product or the left side of the 
origami product. 
 
 
Figure 3.10. Product favored by X and Y primers 
Diagram adapted from Dr. Louis Schoettle. Both X and Y primers favor the origami 
product since it produces a smaller product. These products created by the X and Y 
primers include the necessary BCs but it is unassociated with a α or β gene segment.  
 
Schoettle and Blattman requested a collaboration to resolve this problem with the 
PCR amplification. CP technology was utilized to overcome the formation of the short-
products. CPs consist of a short primer and capture region. When referring to the earlier 
cooperativity models mentioned in the introduction, the functional region of the CP is 
known as the short primer. The short primer consists of a sequence that has a low melting 
temperature (Tm) and thus would not normally amplify a template at higher reaction 
temperature. This short primer is connected to a capture region via a PEG linker. The 
capture region keeps the short primer in close proximity to the template to then encourage 
binding and extension. Connecting the 5’ end of both primers via a PEG linker 
encourages displacement of the capture region following the binding of the short primer  
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due to the strain on the inverted linkage (Satterfield, 2014). This ensures Taq polymerase 
extends from the short primer until the end of the DNA template. Furthermore, the 
capture region has a blocking carbon chain on the 3’ end to ensure Taq polymerase does 
not begin extension from the capture region but rather the short primer (Satterfield, 
2014). Herein this chapter is the design of the two CPs for the bowtie-barcoded origami 
template as well as initial testing (Figure 3.11).  
 
 
Figure 3.11. CP design to bind to Vα and Vβ PCR products 
Diagram adapted from Dr. Louis Schoettle. [A] The left CP is composed of two regions: 
(1) a short primer, X, which binds to X’ and (2) a capture region, Cα’, which binds to Cα. 
The right CP is composed of two regions: (1) a short primer, Y, which binds to Y’ and (2) 
a capture region, Cβ’, which binds to Cβ. A PEG linker connects the short and capture 
regions for both CPs. [B] The capture region first binds to the target sequence, bringing 
the short primer in closer proximity to its target. [C] The inverted PEG linker encourages 
displacement of the capture region as the short primer binds and elongates.  
 
 
 
 
A) 
B) 
C) 
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Materials and Methods 
Brent Satterfield’s mathematical model for CPs was adapted from his earlier 
model derived for cooperative TPs (Satterfield, 2014). Satterfield defined the effective 
primer binding efficiency (Eff) as Eq. (3.1): 
𝐸!! = !!,!"#$!!!"#!!! = (!!"#$! ! !"#$%&#$!!!!! !! !!"#$!!"#)!!!!!!"#!!!   (3.1) 
Where T0 is the initial target concentration and P0 is the initial primer 
concentration. With this model, it is assumed the equilibrium constant of the functional 
region, in this case the short primer, is greater in the presence of a target than non-target 
sequence. Furthermore, the equilibrium constant of the capture region, in this case the 
capture region, is the same in the presence of a target and non-target sequence. This is 
because the target and non-target strand have the same capture regions but differing 
functional regions. However, in the case of the CPs for the bowtie-barcoded origami, the 
equilibrium constant of the short primer in the presence of a target and non-target 
sequence is the same; however, the equilibrium constant of the capture region is greater 
in the presence of a target than non-target sequence. This is because the target and non-
target strand have the same functional regions but differing caption regions. For these 
reasons, the equation to calculate Eff was modified to be Eq. (3.2): 
𝐸!! = !!,!"#!!!"#!!! = (!!"#! ! !"#$%&#$!!!!! !! !!"#$!!"#)!!!!!!"#!!!   (3.2) 
Target sequences of the products created by Vα and Vβ primers were used to 
generate the left CP (compatible with the Vα product) and the right CP (compatible with  
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the Vβ product). The short primer and capture region of the left CP targets X’ and Cα, 
respectively; while the short primer and capture region of the right CP targets Y’ and Cβ, 
respectively (Figure 3.11).  
Creating Short Primer, Capture Region, Target, and Non-Target Sequences. 
In silico prototyping was utilized to perform calculations of possible short primer and 
capture region combinations in the presence of both a target and non-target sequence. For 
the first iteration, short primers for the left CP were generated by taking 15 bps of the 
complement X’ sequence either starting at the 5’ end or ending at the 3’ end of the 20 bp 
sequence. To generate a variety of short primers starting at the 5’ end, one bp was 
removed from the 3’ end to gradually decrease the bp length until it was only 4 bps long. 
This same process was repeated with the short primers ending at the 3’ end; however, the 
one bp was gradually removed from the 5’ end. This process generated 24 varying short 
primers for the left CP. Capture regions for the left CP were generated by taking 22 bps 
of the complement Cα sequence ending at the 3’ end. One bp was then removed from the 
5’ end to gradually decrease the bp length until it was only 10 bps long. This process 
generated 13 varying capture regions for the left CP. This same process was repeated for 
the right CP using the complement Y’ sequence for the short primer and complement Cβ 
sequence for the capture region (see Appendix A for all first iteration sequences). 
Of the left cDNA sequence, 5’-Vα-Jα-Cα-Y-BC-X’-3’, the target sequence for the 
both the short and capture region of the left CP was 5’-Cα-Y-X’-3’. Similarly, of the right 
cDNA sequence, 5’-Vβ-Jβ-Cβ-X-BC-Y’-3’, the target sequence for the short and capture 
region of the right CP was 5’-Cβ-X-Y’-3’. Only Cα/Cβ are retained, as this sequence 
  
49 
remains constant with each mRNA captured, while V, (D), and J are variable due to 
V(D)J recombination. Furthermore, the barcode is excluded, as it will be a different 
sequence with each bowtie-barcoded origami generated. 
Of the bowtie-barcoded origami sequence, 3’-Vα’-Jα’-Cα’-Y’-BC’-X-5’•5’-Y-
BC-X’-Cβ’-Jβ’-Vβ’-3’, the non-target sequence for both the short and capture region of 
the left CP was 5’-Y-X’-Cβ’-3’. Whereas the non-target sequence for both the short and 
capture region of the right CP was 5’-X-Y’-Cα’-3’. The first iteration produced results 
with a primer efficiency that has high in both target and non-target sequences and thus 
required further iterations. 
For the second iteration, short primers for the left and right CP were user-
generated 12 bp sequences with varying %GC content: 66.7, 58.3, and 50. Two 
alternatives were generated per %GC content by altering an A for a T or vice versa to 
create subtle changes in Tm. This process generated six short primers each for the left CP 
and right CP. Capture regions for the left and right CP were the same as the first iteration 
(see Appendix B for second iteration sequences).  
Of the left cDNA sequence, 5’-Vα-Jα-Cα-Yn-BC-X’n-3’, where X’n is the 
complement of the particular X’ short primer being evaluated and Y’n is the complement 
of the particular Y’ short primer being evaluated, the target sequence for the short primer 
of the left CP was 5’-Cα-X’n-3’, and the target sequence for the capture region of the left 
CP was 5’-Cα-3’. Yn was further eliminated from the short primer target, as there would 
need to be 6 target sequences created per left CP short primer to accommodate for all 
possible Yn variations. X’n and Yn were eliminated from the capture region target, as 
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there would need to be 36 target sequences created per left CP capture region to 
accommodate for all possible variations in both X’n and Yn. Ultimately, these 
components were removed from the target sequences to limit the number of outputted 
combinations for Eff. Similarly, of the right cDNA sequence, 5’-Vβ-Jβ-Cβ-Xn-BC-Y’n-3’, 
the target sequence for the short primer of the right CP was 5’-Cβ-Y’n-3’, and the target 
sequence for the capture region of the right CP was 5’-Cβ-3’. 
Of the bowtie-barcoded origami sequence, 3’-Vα’-Jα’-Cα’-Y’n-BC’-Xn-5’•5’-Yn-
BC-X’n-Cβ’-Jβ’-Vβ’-3’, the non-target sequence for the short primer of the left CP was 
5’-X’n-Cβ’-3’, and the non-target sequence for the capture region of the left CP was 5’-
Cβ’-3’.Whereas the non-target sequence for the short primer of the right CP was 5’-Y’n-
Cα’-3’, and the non-target sequence for the capture region of the right CP was 5’-Cα’-3’ 
For the third iteration, the short primers and capture regions with the best Eff 
combination from the second iteration were used, however, the complement of these 12 
bp short primer sequences were incorporated into new, longer 20 bp X’ and Y’ target 
sequences (see Appendix C for third iteration sequences).  
Of the left cDNA sequence, 5’-Vα-Jα-Cα-Y-BC-X’-3’, the target sequence for the 
both the short and capture region of the left CP was 5’-Cα-Y-X’-3’. Similarly, of the right 
cDNA sequence, 5’-Vβ-Jβ-Cβ-X-BC-Y’-3’, the target sequence for the short and capture 
region of the right CP was 5’-Cβ-X-Y’-3’.  
Of the bowtie-barcoded origami sequence, 3’-Vα’-Jα’-Cα’-Y’-BC’-X-5’•5’-Y-
BC-X’-Cβ’-Jβ’-Vβ’-3’, the non-target sequence for both the short and capture region of 
the left CP was 5’-Y-X’-Cβ’-3’. Whereas the non-target sequence for both the short and 
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capture region of the right CP was 5’-X-Y’-Cα’-3’.  
Creating Excel File Mathematical Model. After determining the short primer, 
capture region, target, and non-target sequences, an excel file was created to calculate the 
Eff of the CPs. The file had eight excel sheets: SEQUENCES, CP, LCP THERMO, LCP 
KEFF, LCP EFF, RCP THERMO, RCP KEFF, and RCP EFF (Figure 3.12). The 
SEQUENCES sheet included the sequences making up the bowtie-barcoded origami. 
Using bioinformatics (https://www.bioinformatics.org/sms/rev_comp.html) (“Reverse 
Complement,” n.d.), complements were derived from the sequences and presented in a 5’ 
à 3’ format (Figure 3.12).  
 
 
Figure 3.12. Excel file for CP Design 
There are eight excel sheets used for the CP Design. The SEQUENCES sheet includes all 
target and non-target sequences for the CPs. The CP sheet includes all possible 
combinations of short primers and capture regions for both the left and right CPs. The 
LCP THERMO, LCP KEFF, and LCP EFF all refer to thermodynamic equations for the 
left CP. The RCP THERMO, RCP KEFF, and RCP EFF all refer to thermodynamic 
equations for the right CP. 
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The CP sheet generates the short primer and capture region for both the left CP 
and right CP. Because of the short primer creation differences in the first and second 
iterations, the CP sheet uses different formulas to create the short primers for these 
iterations (Figure 3.13 and 3.14). The third iteration has CP sequences already defined 
based on the output determined by the second iteration, so there is no need to generate 
new short primers and capture regions.  
 
 
Figure 3.13. First iteration short primer and capture region possibilities for both left 
and right CPs 
The top half is possible short primers and capture regions for the left CP. The bottom half 
is possible short primers and capture regions for the right CP. Column B and E are short 
primer possibilities and column I is capture region possibilities.  
 
  
53 
 
Figure 3.14. Second iteration short primer and capture region possibilities for both 
left and right CPs 
The top half is possible short primers and capture regions for the left CP. The bottom half 
is possible short primers and capture regions for the right CP. Column B is short primer 
possibilities and column F is capture region possibilities.  
 
In the first iteration CP sheet (Figure 3.13), for the left CP, cell A3 is 
“=SEQUENCES!H16”, which pulls the 5’ à 3’ complement of X’ from the 
SEQUENCES sheet. Cell B5 is “=LEFT(A3,LEN(A3)-5)”, which removes the last 5 bps 
of the X’ complement sequence defined in cell A3. Cell B6 is “=LEFT(B5,LEN(B5)-1)”, 
which removes the last bp from the sequence defined in the cell above. This formula was 
dragged down to cell B16 to create the first set of 12 short primers. Cell E5 is 
“=RIGHT(A3,LEN(A3)-5)”, which removes the first 5 bps of the X’ complement 
sequenced defined in cell A3. Cell E6 is “=RIGHT(E5,LEN(E5)-1)”, which removes the 
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first bp from sequence defined in the cell above. This formula was dragged down to cell 
E16 to create the last set of 12 short primers. Cell I5 is 
“=LEFT(SEQUENCES!H18,LEN(SEQUENCES!H18)-80)”, which pulls the first 22 bps 
of the 5’ à 3’ complement of  Cα from the SEQUENCES sheet. Cell I6 is 
“=RIGHT(I5,LEN(I5)-1)”, which removes the first bp from sequence defined in the cell 
above. This formula was dragged down to cell E17 to create the capture regions.  
For the right CP, cell A21 is “=SEQUENCES!D15”, which pulls the 5’ à 3’ 
complement of Y’ from the SEQUENCES sheet. Cell B23 is “=LEFT(A21,LEN(A21)-
5)”, which removes the last 5 bps of the Y’ complement sequence defined in cell A21. 
Cell B24 is “=LEFT(B23,LEN(B23)-1)”, which removes the last bp from the sequence 
defined in the cell above. This formula was dragged down to cell B34 to create the first 
set of 12 short primers. Cell E23 is “=RIGHT(A21,LEN(A21)-5)”, which removes the 
first 5 bps of the Y’ complement sequenced defined in cell A21. Cell E24 is 
“=RIGHT(E23,LEN(E23)-1)”, which removes the first bp from sequence defined in the 
cell above. This formula was dragged down to cell E34 to create the last set of 12 short 
primers. Cell I23 is “=LEFT(SEQUENCES!D22,LEN(SEQUENCES!D22)-80)”, which 
pulls the first 22 bps of the 5’ à 3’ complement of  Cβ from the SEQUENCES sheet. 
Cell I24 is “=RIGHT(I23,LEN(I23)-1)”, which removes the first bp from sequence 
defined in the cell above. This formula was dragged down to cell E35 to create the 
capture regions. 
In the second iteration CP sheet (Figure 3.14), for the left CP cell B5 is 
“=SEQUENCES!H15”, which pulls the first 5’ à 3’ complement of X’ from the 
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SEQUENCES sheet. This formula was dragged down to cell B10 to capture all short 
primer variations. Cell F5 is “=LEFT(SEQUENCES!H29,LEN(SEQUENCES!H29)-
80)”, which pulls the first 22 bps of the 5’ à 3’ complement of  Cα from the 
SEQUENCES sheet. Cell F6 is “=RIGHT(F5,LEN(F5)-1)”, which removes the first bp 
from sequence defined in the cell above. This formula was dragged down to cell F17 to 
create the capture regions. 
For the right CP, cell B23 is “=SEQUENCES!D22”, which pulls the first 5’ à 3’ 
complement of Y’ from the SEQUENCES sheet. This formula was dragged down to cell 
B28 to capture all short primer variations. Cell F23 is 
“=LEFT(SEQUENCES!D33,LEN(SEQUENCES!D33)-63)”, which pulls the first 22 bps 
of the 5’ à 3’ complement of  Cβ from the SEQUENCES sheet. Cell F24 is 
“=RIGHT(F23,LEN(F23)-1)”, which removes the first bp from sequence defined in the 
cell above. This formula was dragged down to cell F35 to create the capture regions. 
The LCP THERMO and RCP THERMO sheets hold the thermodynamic values 
for the short primer as well as the capture region in presence of target and non-target 
sequences for the left CP and right CP, respectively. These sheets reformat the ∆H and 
∆S values to be in similar units and calculate the ∆G in terms of a dependent reaction 
temperature. Finally, using these values, the equilibrium constant is calculated. The first, 
second, and third iterations use the same calculations (Figure 3.15). 
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Figure 3.15. Thermodynamic parameters for CP regions in presence of target and 
non-target sequences 
Diagram only shows left CP, but the same sheet is repeated for the right CP but with the 
corresponding sequences. Top half is the thermodynamic parameters for the short primers 
and bottom half is the parameters for the capture regions. Left half corresponds to the 
target sequence and the right half corresponds to the non-target sequence. 
 
The thermodynamic calculations are repeated in four sections of the sheet: (1) 
short primer + target, (2) capture region + target, (3) short primer + non-target, and (4) 
capture region + non-target. Only the first section will be used to demonstrate the 
formulas. Columns D – J are copied and pasted output values from Mfold (Zuker, 2003) 
after entering either the short or capture region sequences as well as either target or non-
target sequence into the program. Cell K7 is “=RIGHT(F7,6)*1”, which removes the 6 
characters in front of the numerical ∆H value from the F7 cell. Cell L7 is 
“=RIGHT(G7,7)*1/1000”, which removes the 6 characters in from of the numerical ∆S 
value from the G7 cell and converts the units from cal K-1 mol-1 to kcal K-1 mol-1 to match 
the units outputted for the ∆H value. The cell M7 is “=K7-($C$4*L7)”, which calculates 
the ∆G value by using the ∆H value generated in cell K7, ∆S value generated in L7, and 
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reaction temp value assigned in cell C4. Finally, cell N7 is “=EXP((-
M7)/($C$2*$C$4))”, which calculates the equilibrium constant of a binding event by 
using the ∆G value generated in cell M7, reaction temp value assigned in cell C4, and 
universal gas constant R value 0.00198 kcal K-1 mol-1 assigned in cell C2. These formulas 
are dragged down for all primer sequences available.  
The LCP KEFF and RCP KEFF sheets calculate the effective equilibrium 
constant (Keff) of the various short primer and capture region combinations in the 
presence of target and non-target sequences for the left CP and right CP, respectively. 
The first, second, and third iterations use the same calculations (Figure 3.16). 
 
 
Figure 3.16. Effective equilibrium constant for all possible combinations of short 
primers and capture regions in presence of target and non-target sequences 
Diagram only shows left CP, but the same sheet is repeated for the right CP but with the 
corresponding sequences. Top half is the effective equilibrium constant for the target 
sequence and the bottom half is for the non-target sequence. 
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The Keff calculations are repeated in two sections of the sheet: (1) short primer 
and capture region combination + target and (2) short primer and capture region 
combination + non-target. Only the first section will be used to demonstrate the formulas. 
Cell B2 is 
“=1/(4/3*PI()*(((1.54*SIN(52.5*(PI()/180))*(B1)+1.43*COS(37.5*(PI()/180))*(2*B1))*
0.1)^3*1E-24*6.023E+23))”, which calculates the increased concentration created by the 
first binding event. The equation uses trigonometry of the C-C and C-O Å bond length of 
an ethylene glycol to calculate the x-distance of the total polyethylene glycol linker. The 
total number of ethylene glycols in the polyethylene glycol is defined in cell B1. This 
number of ethylene glycols is dependent on the number of bps between the end of the 
short primer and beginning of the capture region; one bp is approximately one ethylene 
glycol. This x-distance is then converted from Å to nm and it is cubed, as it is the radius 
of the volumetric space. This value is then multiplied by a unit conversion to convert nm 
to L and then multiplied by Avogadro’s number to convert molecules to mol so the final 
value has M units. Cell B6 is “='LCP THERMO'!$N7+'LCP THERMO'!$N$34+('LCP 
THERMO'!$N7*'LCP THERMO'!$N$34*'LCP KEFF'!$B$2)”, which calculates the Keff 
by adding the equilibrium constant of the short primer binding (from the LCP/RCP 
THERMO sheet) with the equilibrium constant of the capture region binding (from the 
LCP/RCP THERMO sheet) with the equilibrium constant of both primers binding 
(modeled by multiplying the equilibrium constant of short primer binding (LCP/RCP 
THERMO sheet) with the equilibrium constant of capture region binding (LCP/RCP 
THERMO sheet) with the increased local concentration created by the first binding event 
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(cell B2)). This formula is manipulated for all capture sequences available and then 
dragged down for all short primer sequences available. 
 The LCP EFF and RCP EFF sheets calculate the Eff of the various short primer 
and capture region combinations in the presence of target and non-target sequences for 
the left CP and right CP, respectively. The first, second, and third iterations use the same 
calculations (Figure 3.17). 
 
 
Figure 3.17. Primer efficiency for all possible combinations of short primers and 
capture regions in presence of target and non-target sequences 
Diagram only shows left CP, but the same sheet is repeated for the right CP but with the 
corresponding sequences. Top half is the effective equilibrium constant for the target 
sequence and the bottom half is for the non-target sequence. 
 
The Eff calculations are repeated in two sections of the sheet: (1) short primer and 
capture region combination + target and (2) short primer and capture region combination 
+ non-target. Only the first section will be used to demonstrate the formulas. Cell B2  
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references the value of the increased local concentration calculated from the LCP/RCP 
KEFF sheet.  Cell B6 is “=(('LCP THERMO'!$N$34+('LCP THERMO'!$N7*'LCP 
THERMO'!$N$34*'LCP EFF'!$B$2))*'LCP EFF'!$B$1)/(1+('LCP KEFF'!B6*'LCP 
EFF'!$B$1))”, which calculates the Eff using equation Y. The equilibrium constant of the 
capture region binding (from the LCP/RCP THERMO sheet) is added with the 
equilibrium constant of both primers binding (modeled by multiplying the equilibrium 
constant of short primer binding (LCP/RCP THERMO sheet) with the equilibrium 
constant of capture region binding (LCP/RCP THERMO sheet) with the increased local 
concentration created by the first binding event (cell B2)). This value is then divided by 
the corresponding Keff (LCR/RCP KEFF sheet), which is multiplied by the initial primer 
concentration defined in cell B1. This formula is dragged down for all short primer 
sequences available and across for all capture region sequences available.  
Optimal primers were determined by having an Eff  >95% in presence of the target 
sequence and <1% in presence of the non-target sequence. After finding optimal primer 
combinations within the desired Eff ranges, the primers bp length and predicted Tm’s were 
evaluated. Requirements for predicted Tm conditions of the primers and bp length were 
based on Satterfield’s findings (Satterfield, 2014). An optimal combination was 
determined to be a short primer with 10 to 14 bps and a Tm slightly below the Tm of the 
capture region, which is 3°C to 4°C below the reaction temperature. After determining 
the optimal left CP and right CP from the second iteration and validating the combination 
in the third iteration, a custom order was fulfilled with BioSearch (Petaluma, CA). The 
order used a medium synthesis scale and Dual HPLC purification; nomenclature for 
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specific sequences ordered is shown in results (Table 3.1). The “id[C/G/T/A]” 
nomenclature is used to represent an inverted based, so instead of being 5’ à 3’ it is 3’ 
à 5’. To order the specific CPs, a Custom Oligos order form has to be obtained from 
BioSearch. The CP sequences, given in Table 3.1, can then be copied and pasted into the 
Oligo Info sheet under the sequence column. The synthesis scale and purification can 
then be selected for each sequence. 
Evaluating Cooperative Primers. To determine the capture of the α and β 
mRNA, two sample types: (1) origami template (OT) and (2) positive template (PT) were 
prepared for RT. Using a sample size of 20 µL, a 0.2 mL PCR tube was prepared with the 
Omniscript Reverse-Transcription kit (Qiagen) and RNA (from TCRα and TCRβ cells 
extracted from a transgenic mouse spleen). For the OT sample, the origami strand (acting 
as the RT primers) was added and diluted with water to make a final concentration of 0.1 
µM. For the PT sample, Cα and Cβ primers were added and diluted with water to make a 
final concentration of 0.1 µM. These samples were incubated at 37°C for 1 hr to perform 
RT. To determine the optimal annealing conditions of the cooperative primers, a 
temperature annealing gradient using PCR was then conducted on the products generated 
from RT. 
The PCR samples included (1) Cα + Vα – PT, (2) Cβ + Vβ – PT, (3) left CP + Vα 
– OT, (4) right CP + Vβ – OT, (5) left CP + Vα + right CP + Vβ – OT, (6) X + Vα – OT, 
and (7) Y + Vβ – OT. The X and Y primers are the full 20 bp complements of the X’ and 
Y’ sequences of the origami strand, respectively. Samples 1 and 2 are positive controls to 
ensure there are no problems with either the RNA used for the RT or the RT/PCR 
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components. Samples 6 and 7 are positive controls to ensure there are no problems with 
the RT of the origami strand. To prepare the 50 µL PCR samples, 3 µL of the respective 
RT sample was added to a 0.2 mL PCR tube. Primers were added with 2X hot start 
DreamTaq PCR Master Mix (ThermoFisher) and diluted with water make a final 
concentration of 0.2 uM and 1X, respectively.  
An annealing temperature gradient was performed for four temperatures: 45.2°, 
48.5°, 51.4°, and 53.5°C. For the PCR protocol, it was necessary to create two annealing 
temperature steps, as the CPs are designed to bind to the X’ and Y’ products created by 
the Vα and Vβ primers – not the origami strand. Thus, if the products generated by the 
Vα and Vβ primers were never generated, then there would be no target template for the 
CPs. Previous data for Vα and Vβ primers (not shown) demonstrated these primers were 
optimized at 53°C. The PCR protocol was set to have an initial denaturation at 95°C for 
1-3 min, followed by a repeatable process of denaturation at 95°C for 30 s, annealing at 
53°C for 30 s (for the Vα and Vβ primers), extension at 72°C for 30 s, denaturation at 
95°C for 30 s, annealing temperature gradient (45.2°, 48.5°, 51.4°, and 53.5°C) for 2 min 
(for the CPs), and extension at 72°C for 30 s.  
Following PCR, 10µL of each sample was prepared with 2 µL of 6X Gel Loading 
Dye. The 12 µL samples were then run with a 1 Kb plus DNA ladder at 110V for 1 hr on 
a 2% agarose gel prepared with 1X TAE buffer.  
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Results and Discussion 
For the first iteration, Schoettle and Blattman provided the X ‘and Y’ sequences 
from the bowtie-barcoded origami strand, which was based on their pre-constructed 
strand. Because these sequences were pre-defined, the only way to generate a variety of 
short primer sequences was to change the bp length and location of binding. Results 
produced 312 possible combinations of short primers and capture regions. The Eff of the 
left CP indicated that while generally greater than 95% in the presence of the target, the 
minimum Eff in the presence of non-target was 39.45%. For the right CP, the Eff was 
generally greater than 95% in the presence of the target; however, the minimum Eff in the 
presence of non-target was 17.1%.  
For these results, the primers were evaluated assuming a PEG linker distance of 6 
ethylene glycols, equivalent to about 6 bps. This linker length was used as each short 
primer and capture region had a varying bp length in its design, and when used in the 
combination table, this would have produced a different linker length distance for each 
combination. Thus, to simplify this concern, the linker length distance typically used for 
TPs, 6 ethylene glycols, was utilized for the primer efficiency analysis. As indicated by 
the results, none of the Eff’s in the presence of non-target were below 1%, and since there 
were additional design constraints as based on Satterfield’s findings (Satterfield, 2014), it 
was concluded to develop new primers based on backwards design. The first iteration of 
CPs was never ordered; all assessment was conducted in silico. 
For the second iteration, six primers were designed to be 12 bps long, with 
varying %GC content, and with Tm’s ranging from ~40-52°C. The same capture regions 
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were used from the first iteration. For these results, the primers were evaluated assuming 
a PEG linker distance of 24 ethylene glycols, equivalent to about 24 bps. This linker 
length was utilized, as this was the shortest distance that would occur between the short 
primer and capture region. The distance included the 12 bps of the random BC as well as 
the 12 bps of the Y/X segments of the Cα/Cβ products. After determining the optimal left 
and right short primers, the corresponding targets were implemented in the bowtie-
barcoded origami strand. This backwards design didn’t create as many limitations as the 
first iteration and was only possible as the bowtie-barcoded origami strand could be re-
constructed with any determined X’ and Y’ segments.  
Using six variations of short primers and 13 variations of capture regions 
generated 78 combinations. Though there were fewer combinations, better primer 
efficiencies were obtained. The Eff of the left CP ranged from ~76.8% to 99.9% in the 
presence of the target and ~0.4% to 0.6% in the presence of non-target. For the right CP, 
the Eff ranged from ~65.0% to 99.9% in the presence of the target and ~0.3% - 7% in the 
presence of non-target. For the left CP, the best Eff’s were found to be for the 4 short 
primer – 6 capture region sequence, which had a 98.8% binding in the presence of the 
target, and a 0.05% binding in the presence of the non-target. For the right CP, the best 
Eff’s were found to be for the 3 short primer – 7 capture region sequence, which had a 
98.4% binding in the presence of the target, and a 0.08% binding in the presence of the 
non-target.  
These combinations for the left and right CPs were determined to be the best, as 
they fit the necessary Eff conditions and had capture region sequences with a Tm ~51°C 
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and short primer sequences with a Tm ~48°C for the target sequences. Having a Tm below 
the reaction temperature ensure specifics amplification, however, a trade-off with this is 
the possibility of no primer binding occurring. In the case of these capture regions, the Tm 
was below the selected reaction temperature but still indicated formation of product. 
Furthermore, these short primers were chosen, as they had a lower Tm than the capture 
regions. This was necessary as binding of the capture region holds the short primer in 
close proximity to the DNA template, thus increasing the local concentration. This effect 
shifts the Tm of the short primer above the reaction temperature – allowing binding to 
occur (Satterfield, 2014).  
In the third iteration, the optimal short primer and capture region sequences for 
the left and right CPs of the second iteration were utilized. However, Schoettle and 
Blattman required the X’ and Y’ target sequences to actually be 20 bp in length, rather 
than the 12 bps determined from the second iteration. The extension of the X’ and Y’ 
target sequences was deemed as a necessary requirement to create a stronger binding 
affinity between X’ and X and Y’ and Y segments so the bowtie-barcoded component of 
the origami structure could be formed (Figure 3.18).  
 
 
Figure 3.18. Assembly of bowtie-barcoded origami strand 
To assemble the bowtie-barcoded origami strand, there needs to be a strong binding 
affinity between X’ and X and Y’ and Y. This binding followed by PCR creates the arms 
of the origami strand to capture the α and β mRNA strands within the cell.  
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In the calculations, an additional 8 random bps were added to both the X’ and Y’ 
target sequences. Furthermore, now knowing the particular capture region, the actual 
length of the linker could be utilized in the Eff calculations. The linker was updated from 
24 ethylene glycols to 51, equivalent to about 51 bps. This linker length was utilized, as it 
incorporated the 12 bp distance of the random BC, 20 bp distance of the Y/X segments of 
the Cα/Cβ products, 5/6 bp distance of the 5’ à 3’ removal for the Cα/Cβ capture 
sequences, and 12 bp distance of the X’/Y’ segments from the CP due to the need for an 
inverted linkage. This totals to a maximum of 50 bp distance and since each Spacer 9 for 
ordering incorporates 3 ethylene glycols, the distance was rounded to 51 for both the left 
and right CPs. The left CP had a 98.8% binding in the presence of the target, and a 0.01% 
binding in the presence of the non-target. The right CP had a 98.3% binding in the 
presence of the target, and a 0.08% binding in the presence of the non-target. These 
sequences were then ordered from BioSearch (Petaluma, CA) (Table 3.1). 
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Table 3.1. CP sequences ordered from BioSearch  
The [iX] signifies an inverted base pair. 
Left CP 
3’-short primer-5’-LINKER-5’-capture region-3’ 
[idC][idA][iT][idC][idG][idC][idA][idG][idG][idC][idA][iT][Spacer 9][Spacer 9][Spacer 
9][Spacer 9][Spacer 9][Spacer 9][Spacer 9][Spacer 9][Spacer 9][Spacer 9][Spacer 
9][Spacer 9][Spacer 9][Spacer 9][Spacer 9][Spacer 9][Spacer 
9]TTGATTTGGGAGTCAAA[Spacer C3] 
Right CP 
3’-short primer-5’-LINKER-5’-capture region-3’ 
[iT][idA][iT][idG][idG][idC][idC][idC][idC][idA][idC][idA][Spacer 9][Spacer 9][Spacer 
9][Spacer 9][Spacer 9][Spacer 9][Spacer 9][Spacer 9][Spacer 9][Spacer 9][Spacer 
9][Spacer 9][Spacer 9][Spacer 9][Spacer 9][Spacer 9][Spacer 
9]CCTTTTGTTTGTTTGC[Spacer C3] 
 
Results of the annealing temperature gradient (Figure 3.19) indicate the left and 
right CPs are working efficiently at 51.4°C and 53.5°C annealing temperatures (Figure 
3.19.C and 3.19.D, lanes 4 and 5, respectively), as these dark bands closely correspond 
to the X and Y controls (Figure 3.19.C and 3.19.D, lanes 7 and 8, respectively). Even 
though there is a larger by-product also produced by the right CP, both Schoettle and 
Blattman have indicated this is not a concern for identifying the β gene segment. When 
observing the product of the combined left and right CPs, instead of seeing two separate 
bands, around 500 and 400 bps, respectively aligning to the left and right CP controls, 
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there is one large band around 1000 bps (Figure 3.19.C and 3.19.D, lane 6). Because this 
band size is essentially the length of the two separate bands, it was believed this product 
is formed due to hybridization of the respective PCR products (Figure 3.20). 
 
 
Figure 3.19. PCR annealing temperature gradient using Vα, left CP, Vβ, and right 
CP primers 
Lane 1 is 100 bp DNA ladder. Lane 2 is the result of the amplified products from Cα + 
Vα primers. Lane 3 is the result of the amplified products from Cβ + Vβ primers. Lane 4 
is the result of the amplified products from left CP + Vα primers. Lane 5 is the result of 
the amplified products from right CP + Vβ primers. Lane 6 is the result of the amplified 
products from left CP + Vα + right CP + Vβ primers. Lane 7 is result of the amplified 
products from X + Vα primers. Lane 8 is result of the amplified products from Y + 
Vβ primers. [A] Uses a 45.2°C annealing temperature for the CPs. [B] Uses a 48.5°C 
annealing temperature for the CPs. [C] Uses a 51.4°C annealing temperature for the CPs. 
[D] Uses a 53.5°C annealing temperature for the CPs. 
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Figure 3.20. PCR product hybridization using Vα, left CP, Vβ, and right CP 
primers 
The left CP product has the ability to bind to the right CP product, however, these strands 
do not elongate, as Taq polymerase can only synthesize DNA in the 5’ à 3’ direction. 
The Vα product has the ability to bind to the Vβ product, and these strands have the 
potential to elongate, leaving one BC associated with both an α and β mRNA. Because 
the BCs can be complete mismatches and still hybridize it cannot be guaranteed the one 
BC is for both the α and β gene segments tied to it. So it will be unknown which gene 
segment originally identified with the BC and preventing pairing of α and β mRNAs for 
TCR specificity. 
 
Conclusion 
From the results, it could be seen that the Vα + left CP primers specifically 
amplify the left product of interest, which includes the α gene segment paired with a BC. 
It could also be seen that the Vβ + right CP primers specifically amplify the right product 
of interest, which includes the β gene segment paired with a BC. However, when Vα + 
left CP + Vβ + right CP primers are all put together with the same cDNA, the resulting 
product is one that appears to be caused hybridization and elongation of the Vα and Vβ 
products. The hybridization of the Vα to the Vβ product then causes the left CP product 
and right CP product to be single strands as their complements are used in the 
hybridization. For the gel electrophoresis, SYBR safe was used as the DNA stain, so it is 
possible that the single strand products created by the left CP and right CP products are 
there but not visible, as SYBR safe works best for double stranded products due to its  
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intercalating properties. Using a different stain, such as SYBR gold, which is specific to 
single stranded products could further validate this hypothesis. 
In reviewing the design of the CPs, it was noticed that to create the varying 
capture regions, a bp was removed from 5’ à 3’, which actually creates a longer linker. 
It would have been better to remove the bp from 3’ à 5’. However, when comparing the 
linker length of 51 bp used (from the 5’ à 3’ removal) versus the potential 44 bp (from 
the 3’ à 5’ removal), it wouldn’t make a huge difference in the calculation of the 
volumetric space created by the linker: 7.02E-05 compared to 1.09E-04. It would 
however make a difference in the cost of the custom order. A Spacer 9 modification costs 
$30.00/each, so instead of 17 Spacer 9 modifications, equating to $510, it would be 15 
Spacer 9 modifications, equating to $450.  
Both the products created by the left CP and right CP were entered in Mfold 
(Zuker, 2003). The ∆G produced by the hybridization was -19.7 kcal mol-1 with a Tm of 
71.9°C. Even with an additional 12 random bps added between the Y’ and X of the left 
CP product and Y and X’ of the right CP product, Mfold still produced a ∆G of -12.7 kcal 
mol-1 with a Tm of 59.0°C. Because of the range of possibilities for the number of BCs, 
it’s possible not all the 12 bps between the two BCs will mismatch, and if some of them 
do match, it will further decrease the ∆G and encourage hybridization. For these reasons, 
the hybridization of the two products can become favored over the hybridization of the 
Vα or Vβ primers. These products have the potential to hybridize but will not elongate 
since Taq only reads in a 5’ à 3’ directionality. So it is possible when the strands are 
denatured for sequencing, there will still be only one BC with one gene segment. 
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However, this sample is most likely mixed in with the Vα and Vβ hybridized products 
when displayed through gel electrophoresis. 
Furthermore, the products created by the Vα and Vβ products were also entered in 
Mfold (Zuker, 2003). The ∆G produced by the hybridization was -36.2 kcal mol-1 with a 
Tm of 82.0°C. This ∆G is even more negative than the left CP and right CP products as 
there are 40 matching bps compared to 24. Even with an additional 12 random bps added 
between the Y and X’ of the Vα product and Y’ and X of the Vβ product, Mfold still 
produced a ∆G of -29.6 kcal mol-1 with a Tm of 74.1°C – despite the 12 bp mismatch 
between the two product strands. Again, this ∆G can become even more negative if there 
are some matches between the BCs. When comparing the lowest ∆G of hybridization to 
the ∆G of the CP capture regions (-9.0 kcal mol-1 for left CP and -8.8 kcal mol-1 for right 
CP), it can be seen that the product hybridization would be favored over the primers.  
Even if the X’ and Y’ segments were altered for the Cα and Cβ products to 
include a more AT-rich region, thus reducing the %GC content and decreasing the Tm to 
prevent binding at the higher reaction temperature, the hybridized product would still 
most likely occur. This is because if the X’ and Y’ regions are altered to be more AT-
rich, then the corresponding short primers of the CPs would also have to be altered to 
account for the new AT-rich region, thus reducing the Tm of the short primers. As of now, 
there has not been enough research on CPs to know the number of degrees the short 
primer Tm can be below the Tm of the capture region and still function. However, 
Satterfield did demonstrate that as the linker length increased between the short primer 
and capture region, the closer the Tm of the short primer would need to be to the Tm of the 
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capture region (Satterfield, 2014). This is because a longer linker length creates a larger 
spherical space the short primer can travel. The Tm of the short primer is associated with 
the probability of the short primer colliding with the target sequence. As the number of 
collisions increases, Tm of the short primer shifts above the reaction temperature and 
binds. With a long linker length, the frequency of collisions is less so the Tm of the short 
primer needs to be closer to the Tm of the capture region.  
It’s also possible that the Vα or Vβ primers could anneal to one of the hybridized 
products and elongate. This has the potential of associating the wrong BC with the wrong 
gene segment. If the 3’ end of the template could be blocked after elongation of the Vα 
and Vβ primer, then this would prevent elongation of the product-product hybridization 
and ensure the BC is associated with the correct α or β gene segment. As described 
earlier, the hybridized result seems to be inevitable with every design choice. However, 
the initial strand used to make the origami could potentially be altered to introduce two 
different BCs in the final hybridized product; one BC next to the α gene segment and one 
next to the β (Figure 3.21). This relocation of the BC would even further encourage 
product-product hybridization, as it would prevent the possible 12 bp mismatch and thus 
produce the lowest possible ∆G’s. However, since the Y’, Y, X’, and X sequences are 
known and since the location of the BC is known to be next to the Cα, Cα’, Cβ, or Cβ’ 
sequences, then during sequencing, each gene segment can be associated with its correct 
BC despite product hybridization. Furthermore, relocation of the BC would not require 
new CPs to be designed, as it does not impact the short primer, capture region, or linker 
length. This idea was proposed to Schoettle, however, this would be unfeasible, as IDT 
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DNA cannot guarantee that the first randomly generated 12 bp sequences for the BC are 
exactly replicated later on in the sequence.  
Future research suggests proceeding with the current bowtie-barcoded origami 
strand and current primers but finding a way to verify if the left CP and right CP products 
are hybridized but able to form the desired products upon denaturation. Future work 
should run the samples using a denaturing gradient gel electrophoresis to separate the 
hybridized strands. Theoretically, this should produce three bands with the topmost band 
being the Vα and Vβ hybridized products, which can be disregarded.  
If the hybridization of the system were to be resolved or if the BCs of the 
hybridized product are identified to its α or β gene segment, then this system has the 
potential to develop novel immunotherapies, such as cancer therapies. Tumor infiltrating 
lymphocytes (TILs) are tumor-antigen-specific T cells that can be isolated following 
removal of the tumor tissue (Sharpe & Mount, 2015). Tumor-specific T cells can then be 
engineered as based on the identification of the α and β chains of the TIL receptors. 
Previous clinical research on TCR therapy has demonstrated overall tumor regression and 
showed no signs of significant toxicity, thus providing the possibility of a promising 
cancer therapy (Sharpe & Mount, 2015). However, mispairing of the α and β chains of 
the receptor can impact both efficacy and safety so it is necessary to ensure the bowtie-
barcoded origami system is specific and accurate and relays the correct α and β chain to 
the correct BC. 
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Figure 3.21. Proposed two barcode origami strand 
This system would create two BCs in the hybridized product and ensure each α and β 
gene segment was associated to its own BC, however, IDT DNA cannot generate 12 
random bp for the first barcode and ensure the same 12 bps are repeated later on in the 
sequence for the second barcode.   
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Table A.1. Target and non-target sequences for left CP  
Target: 5’-Vα-Jα-Cα-Y-BC-X’-3’ 
Cα 
5’-ACATCCAGAACCCAGAACCTGCTGTGTACCAGTTAAAAGATCC 
TCGGTCTCAGGACAGCACCCTCTGCCTGTTCACCGACTTTGACTC
CCAAATCAATGTGC-3’ 
Y 5’-GGACAGCAAAGACAGCACCT-3’ 
X’ 5’-GCTCAGGGAAATAGCCCTTG-3’ 
Cα-Y-X’ 
5’-ACATCCAGAACCCAGAACCTGCTGTGTACCAGTTAAAAGATCC 
TCGGTCTCAGGACAGCACCCTCTGCCTGTTCACCGACTTTGACTC
CCAAATCAATGTGCGGACAGCAAAGACAGCACCTGCTCAGGGAA
A TAGCCCTTG-3’ 
Non-Target: 5’-Y-BC-X’-Cβ’-Jβ’-Dβ’-Vβ’-3’ 
Y 5’-GGACAGCAAAGACAGCACCT-3’ 
X’ 5’-GCTCAGGGAAATAGCCCTTG-3’ 
Cβ’ 
5’-GGGTAGCCTTTTGTTTGTTTGCAATCTCTGCTTTTGATGGCTCA 
AACAAGGAGACCTTGGGTGGAGTCACATTTCTCAGATCCTC -3’ 
Y-X’-Cβ’ 
5’- GGACAGCAAAGACAGCACCTGCTCAGGGAAATAGCCCTTGGG 
GTAGCCTTTTGTTTGTTTGCAATCTCTGCTTTTGATGGCTCAAACA
AGGAGACCTTGGGTGGAGTCACATTTCTCAGATCCTC-3’ 
  
  
80 
Table A.2. Target and non-target sequences for right CP 
Target: 5’-Vβ-Dβ-Jβ-Cβ-X-BC-Y’-3’ 
Cβ 
5’- GAGGATCTGAGAAATGTGACTCCACCCAAGGTCTCCTTGTTTG 
AGCCATCAAAAGCAGAGATTGCAAACAAACAAAAGGCTACCC-3’ 
X 5’-CAAGGGCTATTTCCCTGAGC-3’ 
Y’ 5’-AGGTGCTGTCTTTGCTGTCC-3’ 
Cβ-X-Y’ 
5’-GAGGATCTGAGAAATGTGACTCCACCCAAGGTCTCCTTGTTTG 
AGCCATCAAAAGCAGAGATTGCAAACAAACAAAAGGCTACCCCA
AGGGCTATTTCCCTGAGCAGGTGCTGTCTTTGCTGTCC-3’ 
Non-Target: 5’-X-Y’-Cα’-Jα’-Vα’-3’ 
X 5’-CAAGGGCTATTTCCCTGAGC-3’ 
Y’ 5’-AGGTGCTGTCTTTGCTGTCC-3’ 
Cα’ 
5’-GCACATTGATTTGGGAGTCAAAGTCGGTGAACAGGCAGAGGG 
TGCTGTCCTGAGACCGAGGATCTTTTAACTGGTACACAGCAGGTT
CTGGGTTCTGGATGT-3’ 
X-Y’- Cα’ 
5’-CAAGGGCTATTTCCCTGAGCAGGTGCTGTCTTTGCTGTCCGCA 
CATTGATTTGGGAGTCAAAGTCGGTGAACAGGCAGAGGGTGCTG
TCCTGAGACCGAGGATCTTTTAACTGGTACACAGCAGGTTCTGGG
TTCTGGATGT-3’ 
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Table A.3. Short primer sequences for left CP 
5’-GCTCAGGGAAATAGCCCTTG-3’ 
Short Primer # 
Primer Sequence (5’ à  3’) 
1bp removal from 5’ à 3’ bp 
1 CAAGGGCTATTTCCC 15 
2 CAAGGGCTATTTCC 14 
3 CAAGGGCTATTTC 13 
4 CAAGGGCTATTT 12 
5 CAAGGGCTATT 11 
6 CAAGGGCTAT 10 
7 CAAGGGCTA 9 
8 CAAGGGCT 8 
9 CAAGGGC 7 
10 CAAGGG 6 
11 CAAGG 5 
12 CAAG 4 
5’-GCTCAGGGAAATAGCCCTTG-3’ 
Short Primer # 
Primer Sequence (5’ à  3’) 
1bp removal from 5’ à 3’ bp 
13 GCTATTTCCCTGAGC 15 
14 CTATTTCCCTGAGC 14 
15 TATTTCCCTGAGC 13 
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16 ATTTCCCTGAGC 12 
17 TTTCCCTGAGC 11 
18 TTCCCTGAGC 10 
19 TCCCTGAGC 9 
20 CCCTGAGC 8 
21 CCTGAGC 7 
22 CTGAGC 6 
23 TGAGC 5 
24 GAGC 4 
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Table A.4. Capture region sequences for left CP 
Capture Region # 
Primer Sequence (5’ à  3’) 
1bp removal from 5’ à 3’ bp 
1 GCACATTGATTTGGGAGTCAAA 22 
2 CACATTGATTTGGGAGTCAAA 21 
3 ACATTGATTTGGGAGTCAAA 20 
4 CATTGATTTGGGAGTCAAA 19 
5 ATTGATTTGGGAGTCAAA 18 
6 TTGATTTGGGAGTCAAA 17 
7 TGATTTGGGAGTCAAA 16 
8 GATTTGGGAGTCAAA 15 
9 ATTTGGGAGTCAAA 14 
10 TTTGGGAGTCAAA 13 
11 TTGGGAGTCAAA 12 
12 TGGGAGTCAAA 11 
13 GGGAGTCAAA 10 
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Table A.5. Short primer sequences for right CP 
5’-AGGTGCTGTCTTTGCTGTCC-3’ 
Short Primer # 
Primer Sequence (5’ à  3’) 
1bp removal from 3’ à 5’ bp 
1 GGACAGCAAAGACAG 15 
2 GGACAGCAAAGACA 14 
3 GGACAGCAAAGAC 13 
4 GGACAGCAAAGA 12 
5 GGACAGCAAAG 11 
6 GGACAGCAAA 10 
7 GGACAGCAA 9 
8 GGACAGCA 8 
9 GGACAGC 7 
10 GGACAG 6 
11 GGACA 5 
12 GGAC 4 
Closer to 5’-AGGTGCTGTCTTTGCTGTCC-3’ 
Short Primer # 
Primer Sequence (5’ à  3’) 
1bp removal from 5’ à 3’ bp 
13 GCAAAGACAGCACCT 15 
14 CAAAGACAGCACCT 14 
15 AAAGACAGCACCT 13 
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16 AAGACAGCACCT 12 
17 AGACAGCACCT 11 
18 GACAGCACCT 10 
19 ACAGCACCT 9 
20 CAGCACCT 8 
21 AGCACCT 7 
22 GCACCT 6 
23 CACCT 5 
24 ACCT 4 
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Table A.6. Capture region sequences for right CP 
Capture Region # 
Primer Sequence (5’ à  3’) 
1bp removed from 5’à3’ bp 
1 GGGTAGCCTTTTGTTTGTTTGC 22 
2 GGTAGCCTTTTGTTTGTTTGC 21 
3 GTAGCCTTTTGTTTGTTTGC 20 
4 TAGCCTTTTGTTTGTTTGC 19 
5 AGCCTTTTGTTTGTTTGC 18 
6 GCCTTTTGTTTGTTTGC 17 
7 CCTTTTGTTTGTTTGC 16 
8 CTTTTGTTTGTTTGC 15 
9 TTTTGTTTGTTTGC 14 
10 TTTGTTTGTTTGC 13 
11 TTGTTTGTTTGC 12 
12 TGTTTGTTTGC 11 
13 GTTTGTTTGC 10 
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APPENDIX B  
SECOND ITERATION SEQUENCES FOR COOPERATIVE PRIMERS 
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Table B.1. Short primer sequences for left CP 
Short 
Primer 
# 
Primer Sequence 
(5’ à  3’) 
%GC 
Content 
Target/Non-Target Sequences 
(5’ à  3’) 
1 AACGGACGCAGC 66.7 
Target: ACATCCAGAACCCAGAACCT 
GCTGTGTACCAGTTAAAGATCCTCG
GTCTCAGGACAGCACCCTCTGCCTG
TTCACCGACTTTGACTCCCAAATCAA
TGTGCGCTGCGTCCGTT 
Non-Target: GCTGCGTCCGTTGGGTA 
GCCTTTTGTTTGTTTGCAATCTCTGC
TTTTGATGGCTCAAACAAGGAGACC
TTGGGTGGAGTCACATTTCTCAGATC
CTC 
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2 TACGGACGCAGC 66.7 
Target: ACATCCAGAACCCAGAACCT 
GCTGTGTACCAGTTAAAAGATCCTC
GGTCTCAGGACAGCACCCTCTGCCT
GTTCACCGACTTTGACTCCCAAATCA
ATGTGCTGCGTCCGTA 
Non-Target: GCTGCGTCCGTAGGGTA 
GCCTTTTGTTTGTTTGCAATCTCTGC
TTTTGATGGCTCAAACAAGGAGACC
TTGGGTGGAGTCACATTTCTCAGATC
CTC 
3 TACGGACGCAAC 58.3 
Target: ACATCCAGAACCCAGAACCT 
GCTGTGTACCAGTTAAAAGATCCTC
GGTCTCAGGACAGCACCCTCTGCCT
GTTCACCGACTTTGACTCCCAAATCA
ATGTGTTGCGTCCGTA 
Non-Target: GTTGCGTCCGTAGGGTA 
GCCTTTTGTTTGTTTGCAATCTCTGC
TTTTGATGGCTCAAACAAGGAGACC
TTGGGTGGAGTCACATTTCTCAGATC
CTC 
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4 TACGGACGCTAC 58.3 
Target: ACATCCAGAACCCAGAACCT 
GCTGTGTACCAGTTAAAAGATCCTC
GGTCTCAGGACAGCACCCTCTGCCT
GTTCACCGACTTTGACTCCCAAATCA
ATGTGTAGCGTCCGTA 
Non-Target: GTAGCGTCCGTAGGGTA 
GCCTTTTGTTTGTTTGCAATCTCTGC
TTTTGATGGCTCAAACAAGGAGACC
TTGGGTGGAGTCACATTTCTCAGATC
CTC 
5 TACGAACGCAAC 50.0 
Target: ACATCCAGAACCCAGAACCT 
GCTGTGTACCAGTTAAAAGATCCTC
GGTCTCAGGACAGCACCCTCTGCCT
GTTCACCGACTTTGACTCCCAAATCA
ATGTGTTGCGTTCGTA 
Non-Target: GTTGCGTTCGTAGGGTA 
GCCTTTTGTTTGTTTGCAATCTCTGC
TTTTGATGGCTCAAACAAGGAGACC
TTGGGTGGAGTCACATTTCTCAGATC
CTC 
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6 TACGATCGCAAC 50.0 
Target: ACATCCAGAACCCAGAACCT 
GCTGTGTACCAGTTAAAAGATCCTC
GGTCTCAGGACAGCACCCTCTGCCT
GTTCACCGACTTTGACTCCCAAATCA
ATGTGTTGCGATCGTA 
Non-Target: GTTGCGATCGTAGGGTA 
GCCTTTTGTTTGTTTGCAATCTCTGC
TTTTGATGGCTCAAACAAGGAGACC
TTGGGTGGAGTCACATTTCTCAGATC
CTC 
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Table B.2. Capture region sequences for left CP 
Target Sequence: 5’-ACATCCAGAACCCAGAACCTGCTGTGTACCAGTTAAAAG 
ATCCTCGGTCTCAGGACAGCACCCTCTGCCTGTTCACCGACTTTGACTCCCAA
ATCAATGTGC-3’ 
Non-Target Sequence: 5’-GGGTAGCCTTTTGTTTGTTTGCAATCTCTGCTTTTGA 
TGGCTCAAACAAGGAGACCTTGGGTGGAGTCACATTTCTCAGATCCTC-3’ 
Primer # 
Primer Sequence 
(5’ à  3’) 
1bp removal from 5’ à 3’ 
1 GCACATTGATTTGGGAGTCAAA 
2 CACATTGATTTGGGAGTCAAA 
3 ACATTGATTTGGGAGTCAAA 
4 CATTGATTTGGGAGTCAAA 
5 ATTGATTTGGGAGTCAAA 
6 TTGATTTGGGAGTCAAA 
7 TGATTTGGGAGTCAAA 
8 GATTTGGGAGTCAAA 
9 ATTTGGGAGTCAAA 
10 TTTGGGAGTCAAA 
11 TTGGGAGTCAAA 
12 TGGGAGTCAAA 
13 GGGAGTCAAA 
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Table B.3. Short primer sequences for left CP 
Short 
Primer 
# 
Primer Sequence 
(5’ à  3’) 
%GC 
Content 
Target/Non-Target Sequences  
(5’ à  3’) 
1 GCACCCCGGAAT 66.7 
Target: GAGGATCTGAGAAATGTGACT 
CCACCCAAGGTCTCCTTGTTTGAGCCA
TCAAAAGCAGAGATTGCAAACAAACA
AAAGGCTACCCATTCCGGGGTGC 
Non-Target: ATTCCGGGGTGCGCACAT 
TGATTTGGGAGTCAAAGTCGGTGAAC
AGGCAGAGGGTGCTGTCCTGAGACCG
AGGATCTTTTAACTGGTACACAGCAG
GTTCTGGGTTCTGGATGT 
2 GCACCCCGGTAT 66.7 
Target: GAGGATCTGAGAAATGTGACT 
CCACCCAAGGTCTCCTTGTTTGAGCCA
TCAAAAGCAGAGATTGCAAACAAACA
AAAGGCTACCCATACCGGGGTGC 
Non-Target: ATACCGGGGTGCGCACAT 
TGATTTGGGAGTCAAAGTCGGTGAAC
AGGCAGAGGGTGCTGTCCTGAGACCG
AGGATCTTTTAACTGGTACACAGCAG
GTTCTGGGTTCTGGATGT 
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3 ACACCCCGGTAT 58.3 
Target: GAGGATCTGAGAAATGTGACT 
CCACCCAAGGTCTCCTTGTTTGAGCCA
TCAAAAGCAGAGATTGCAAACAAACA
AAAGGCTACCCATACCGGGGTGT 
Non-Target: ATACCGGGGTGTGCACAT 
TGATTTGGGAGTCAAAGTCGGTGAAC
AGGCAGAGGGTGCTGTCCTGAGACCG
AGGATCTTTTAACTGGTACACAGCAG
GTTCTGGGTTCTGGATGT 
4 ACACCCCGGAAT 58.3 
Target: GAGGATCTGAGAAATGTGACT 
CCACCCAAGGTCTCCTTGTTTGAGCCA
TCAAAAGCAGAGATTGCAAACAAACA
AAAGGCTACCCATTCCGGGGTGT 
Non-Target: ATTCCGGGGTGTGCACAT 
TGATTTGGGAGTCAAAGTCGGTGAAC
AGGCAGAGGGTGCTGTCCTGAGACCG
AGGATCTTTTAACTGGTACACAGCAG
GTTCTGGGTTCTGGATGT 
  
95 
5 AAACCCCGGAAT 50.0 
Target: GAGGATCTGAGAAATGTGACT 
CCACCCAAGGTCTCCTTGTTTGAGCCA
TCAAAAGCAGAGATTGCAAACAAACA
AAAGGCTACCCATTCCGGGGTTT 
Non-Target: ATTCCGGGGTTTGCACAT 
TGATTTGGGAGTCAAAGTCGGTGAAC
AGGCAGAGGGTGCTGTCCTGAGACCG
AGGATCTTTTAACTGGTACACAGCAG
GTTCTGGGTTCTGGATGT 
6 AATCCCCGGAAT 50.0 
Target: GAGGATCTGAGAAATGTGACT 
CCACCCAAGGTCTCCTTGTTTGAGCCA
TCAAAAGCAGAGATTGCAAACAAACA
AAAGGCTACCCATTCCGGGGATT 
Non-Target: ATTCCGGGGATTGCACAT 
TGATTTGGGAGTCAAAGTCGGTGAAC
AGGCAGAGGGTGCTGTCCTGAGACCG
AGGATCTTTTAACTGGTACACAGCAG
GTTCTGGGTTCTGGATGT 
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Table B.4. Capture region sequences for right CP 
Target: 5’-GAGGATCTGAGAAATGTGACTCCACCCAAGGTCTCCTTGTTTGAGC 
CATCAAAAGCAGAGATTGCAAACAAACAAAAGGCTACCC-3’ 
Non-Target: 5’-GCACATTGATTTGGGAGTCAAAGTCGGTGAACAGGCAGAGGG 
TGCTGTCCTGAGACCGAGGATCTTTTAACTGGTACACAGCAGGTTCTGGGTTC
TGGATGT-3’ 
Capture Region # 
Primer Sequence (5’ à  3’) 
1bp removed from 5’à3’ bp 
1 GGGTAGCCTTTTGTTTGTTTGC 22 
2 GGTAGCCTTTTGTTTGTTTGC 21 
3 GTAGCCTTTTGTTTGTTTGC 20 
4 TAGCCTTTTGTTTGTTTGC 19 
5 AGCCTTTTGTTTGTTTGC 18 
6 GCCTTTTGTTTGTTTGC 17 
7 CCTTTTGTTTGTTTGC 16 
8 CTTTTGTTTGTTTGC 15 
9 TTTTGTTTGTTTGC 14 
10 TTTGTTTGTTTGC 13 
11 TTGTTTGTTTGC 12 
12 TGTTTGTTTGC 11 
13 GTTTGTTTGC 10 
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APPENDIX C  
THIRD ITERATION SEQUENCES FOR COOPERATIVE PRIMERS 
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Table C.1. Primer sequences for left CP  
Target Sequence: 5’-ACATCCAGAACCCAGAACCTGCTGTGTACCAGTTAAAAG  
ATCCTCGGTCTCAGGACAGCACCCTCTGCCTGTTCACCGACTTTGACTCCCAA
ATCAATGTGCGCCGGATCACACCCCGGTATGTAGCGTCCGTAGCCCGTGG-3’ 
Non-Target Sequence: 5’-GCCGGATCACACCCCGGTATGTAGCGTCCGTAGCCC 
GTGGGGGTAGCCTTTTGTTTGTTTGCAATCTCTGCTTTTGATGGCTCAAACAA
GGAGACCTTGGGTGGAGTCACATTTCTCAGATCCTC-3’ 
Primer Type Primer Sequence (5’ à  3’) 
Short TACGGACGCTAC 
Capture TTGATTTGGGAGTCAAA 
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Table C.2. Primer sequences for right CP  
Target: 5’-GAGGATCTGAGAAATGTGACTCCACCCAAGGTCTCCTTGTTTGAGC 
CATCAAAAGCAGAGATTGCAAACAAACAAAAGGCTACCCCCACGGGCTACG
GACGCTACATACCGGGGTGTGATCCGGC-3’ 
Non-Target: 5’-CCACGGGCTACGGACGCTACATACCGGGGTGTGATCCGGCGC 
ACATTGATTTGGGAGTCAAAGTCGGTGAACAGGCAGAGGGTGCTGTCCTGAG
ACCGAGGATCTTTTAACTGGTACACAGCAGGTTCTGGGTTCTGGATGT-3’ 
Primer Type Primer Sequence (5’ à  3’) 
Short ACACCCCGGTAT 
Capture CCTTTTGTTTGTTTGC 
 
